{
  "doc_id": "29",
  "paragraphs": [
    {
      "paragraph_id": "0",
      "paragraph": "糖尿病微循环障碍临床用药专家共识",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "糖尿病微循环障碍临床用药专家共识",
          "start_idx": 0,
          "end_idx": 16,
          "entities": [
            {
              "entity_id": "T0",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 3,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T1",
              "entity": "微循环障碍",
              "entity_type": "Symptom",
              "start_idx": 3,
              "end_idx": 8,
              "entity_en": "Microcirculatory disorders"
            }
          ],
          "relations": [
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R0",
              "head_entity_id": "T1",
              "tail_entity_id": "T0"
            }
          ],
          "sentence_en": "Expert consensus on clinical medication for diabetic microcirculatory disorders"
        }
      ],
      "paragraph_en": "Expert consensus on clinical medication for diabetic microcirculatory disorders"
    },
    {
      "paragraph_id": "1",
      "paragraph": "1 背景",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1 背景",
          "start_idx": 0,
          "end_idx": 4,
          "entities": [],
          "relations": [],
          "sentence_en": "1 Background"
        }
      ],
      "paragraph_en": "1 Background"
    },
    {
      "paragraph_id": "2",
      "paragraph": "糖尿病及其慢性并发症可导致患者肾功能衰竭、失明、截肢和心脑血管事件，致残率和致死率高，给患者的健康和生命造成了严重威胁。微障碍是糖尿病慢性并发症发生的重要病理生理基础之一，在控制血糖的同时改善微循环障碍，对于预防、延缓、治疗糖尿病各种慢性并发症具有十分重要的意义。当前临床工作中，对于微循环障碍在糖尿病慢性并发症发生发展中的作用及机制，认识尚不充分，相关药物的选择与使用欠规范。鉴于此，中国微循环学会糖尿病与微循环专业委员会制订此共识，以期为临床合理选择改善糖尿病微循环障碍药物提供参考。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "糖尿病及其慢性并发症可导致患者肾功能衰竭、失明、截肢和心脑血管事件，致残率和致死率高，给患者的健康和生命造成了严重威胁。微障碍是糖尿病慢性并发症发生的重要病理生理基础之一，在控制血糖的同时改善微循环障碍，对于预防、延缓、治疗糖尿病各种慢性并发症具有十分重要的意义。",
          "start_idx": 0,
          "end_idx": 132,
          "entities": [
            {
              "entity_id": "T2",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 3,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T3",
              "entity": "肾功能衰竭",
              "entity_type": "Disease",
              "start_idx": 15,
              "end_idx": 20,
              "entity_en": "Renal failure"
            },
            {
              "entity_id": "T4",
              "entity": "失明",
              "entity_type": "Disease",
              "start_idx": 21,
              "end_idx": 23,
              "entity_en": "blindness"
            },
            {
              "entity_id": "T5",
              "entity": "截肢",
              "entity_type": "Operation",
              "start_idx": 24,
              "end_idx": 26,
              "entity_en": "Amputation"
            },
            {
              "entity_id": "T6",
              "entity": "心脑血管事件",
              "entity_type": "Disease",
              "start_idx": 27,
              "end_idx": 33,
              "entity_en": "Cardiovascular and cerebrovascular events"
            },
            {
              "entity_id": "T7",
              "entity": "微障碍",
              "entity_type": "Symptom",
              "start_idx": 60,
              "end_idx": 63,
              "entity_en": "Micro-obstacles"
            },
            {
              "entity_id": "T8",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 112,
              "end_idx": 115,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T11",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 15,
              "end_idx": 16,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T12",
              "entity": "心脑血管",
              "entity_type": "Anatomy",
              "start_idx": 27,
              "end_idx": 31,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T13",
              "entity": "微循环障碍",
              "entity_type": "Symptom",
              "start_idx": 96,
              "end_idx": 101,
              "entity_en": "Microcirculatory disorders"
            },
            {
              "entity_id": "T14",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 89,
              "end_idx": 91,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T15",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 64,
              "end_idx": 67,
              "entity_en": "diabetes"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R1",
              "head_entity_id": "T11",
              "tail_entity_id": "T3"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R2",
              "head_entity_id": "T12",
              "tail_entity_id": "T6"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R3",
              "head_entity_id": "T7",
              "tail_entity_id": "T15"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R4",
              "head_entity_id": "T14",
              "tail_entity_id": "T8"
            }
          ],
          "sentence_en": "Diabetes and its chronic complications can lead to renal failure, blindness, amputation and cardiovascular and cerebrovascular events, with high disability and mortality rates, posing a serious threat to patients' health and life. Microcirculation disorders are one of the important pathophysiological bases for the occurrence of chronic complications of diabetes. Improving microcirculatory disorders while controlling blood sugar is of great significance for preventing, delaying and treating various chronic complications of diabetes."
        },
        {
          "sentence_id": "1",
          "sentence": "当前临床工作中，对于微循环障碍在糖尿病慢性并发症发生发展中的作用及机制，认识尚不充分，相关药物的选择与使用欠规范。",
          "start_idx": 132,
          "end_idx": 189,
          "entities": [
            {
              "entity_id": "T9",
              "entity": "微循环障碍",
              "entity_type": "Symptom",
              "start_idx": 10,
              "end_idx": 15,
              "entity_en": "Microcirculatory disorders"
            },
            {
              "entity_id": "T16",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 16,
              "end_idx": 19,
              "entity_en": "diabetes"
            }
          ],
          "relations": [
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R5",
              "head_entity_id": "T9",
              "tail_entity_id": "T16"
            }
          ],
          "sentence_en": "In current clinical work, there is still insufficient understanding of the role and mechanism of microcirculation disorders in the occurrence and development of chronic complications of diabetes, and the selection and use of related drugs are not standardized."
        },
        {
          "sentence_id": "2",
          "sentence": "鉴于此，中国微循环学会糖尿病与微循环专业委员会制订此共识，以期为临床合理选择改善糖尿病微循环障碍药物提供参考。",
          "start_idx": 189,
          "end_idx": 244,
          "entities": [
            {
              "entity_id": "T10",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 11,
              "end_idx": 14,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T17",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 40,
              "end_idx": 43,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T18",
              "entity": "微循环障碍",
              "entity_type": "Symptom",
              "start_idx": 43,
              "end_idx": 48,
              "entity_en": "Microcirculatory disorders"
            }
          ],
          "relations": [
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R6",
              "head_entity_id": "T18",
              "tail_entity_id": "T17"
            }
          ],
          "sentence_en": "In view of this, the Diabetes and Microcirculation Professional Committee of the Chinese Microcirculation Society has formulated this consensus in order to provide a reference for the rational clinical selection of drugs to improve diabetic microcirculation disorders."
        }
      ],
      "paragraph_en": "Diabetes and its chronic complications can lead to renal failure, blindness, amputation and cardiovascular and cerebrovascular events, with high disability and mortality rates, posing a serious threat to patients' health and life. Microcirculation disorders are one of the important pathophysiological bases for the occurrence of chronic complications of diabetes. Improving microcirculatory disorders while controlling blood sugar is of great significance for preventing, delaying and treating various chronic complications of diabetes. In current clinical work, there is still insufficient understanding of the role and mechanism of microcirculatory disorders in the occurrence and development of chronic complications of diabetes, and the selection and use of related drugs are not standardized. In view of this, the Diabetes and Microcirculation Professional Committee of the Chinese Microcirculation Society has formulated this consensus in order to provide a reference for the rational selection of drugs to improve diabetic microcirculatory disorders in clinical practice."
    },
    {
      "paragraph_id": "3",
      "paragraph": "2 糖尿病微循环障碍的定义",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2 糖尿病微循环障碍的定义",
          "start_idx": 0,
          "end_idx": 13,
          "entities": [
            {
              "entity_id": "T19",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 5,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T20",
              "entity": "微循环障碍",
              "entity_type": "Symptom",
              "start_idx": 5,
              "end_idx": 10,
              "entity_en": "Microcirculatory disorders"
            }
          ],
          "relations": [
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R7",
              "head_entity_id": "T20",
              "tail_entity_id": "T19"
            }
          ],
          "sentence_en": "2 Definition of diabetic microcirculatory disorders"
        }
      ],
      "paragraph_en": "2 Definition of diabetic microcirculatory disorders"
    },
    {
      "paragraph_id": "4",
      "paragraph": "2.1 微循环障碍微循环由微动脉、后微动脉、毛细血管前括约肌、真毛细血管、动-静脉吻合支和微静脉及其流经其内的液体所组成，是循环系统的基础结构，也是血液与组织间实现物质交换的主要场所和功能单位。在炎症反应、代谢障碍等病理情况下，可发生血管细胞功能障碍，自主神经功能异常及内分泌激素分泌紊乱，导致微血管舒缩功能紊乱、血管壁通透性升高以及血液流变性变化，并可出现微血管结构和毛细血管密度的异常，影响组织的物质交换和器官功能。这种病理情况下，微循环结构及功能的异常导致其不能与组织和器官代谢水平相适应，影响组织的物质交换和器官功能状态称之为微循环障碍。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2.1 微循环障碍微循环由微动脉、后微动脉、毛细血管前括约肌、真毛细血管、动-静脉吻合支和微静脉及其流经其内的液体所组成，是循环系统的基础结构，也是血液与组织间实现物质交换的主要场所和功能单位。",
          "start_idx": 0,
          "end_idx": 97,
          "entities": [
            {
              "entity_id": "T21",
              "entity": "微循环障碍",
              "entity_type": "Symptom",
              "start_idx": 4,
              "end_idx": 9,
              "entity_en": "Microcirculatory disorders"
            }
          ],
          "relations": [],
          "sentence_en": "2.1 Microcirculatory disorders Microcirculation is composed of arterioles, post-arterioles, precapillary sphincters, true capillaries, arteriovenous anastomoses and venules, as well as the fluid flowing through them. It is the basic structure of the circulatory system and the main place and functional unit for substance exchange between blood and tissues."
        },
        {
          "sentence_id": "1",
          "sentence": "在炎症反应、代谢障碍等病理情况下，可发生血管细胞功能障碍，自主神经功能异常及内分泌激素分泌紊乱，导致微血管舒缩功能紊乱、血管壁通透性升高以及血液流变性变化，并可出现微血管结构和毛细血管密度的异常，影响组织的物质交换和器官功能。",
          "start_idx": 97,
          "end_idx": 210,
          "entities": [
            {
              "entity_id": "T23",
              "entity": "炎症反应",
              "entity_type": "Reason",
              "start_idx": 1,
              "end_idx": 5,
              "entity_en": "Inflammatory response"
            },
            {
              "entity_id": "T24",
              "entity": "代谢障碍",
              "entity_type": "Reason",
              "start_idx": 6,
              "end_idx": 10,
              "entity_en": "Metabolic disorders"
            }
          ],
          "relations": [],
          "sentence_en": "Under pathological conditions such as inflammatory response and metabolic disorders, vascular cell dysfunction, autonomic nervous system dysfunction and endocrine hormone secretion disorder may occur, leading to microvascular vasomotor dysfunction, increased vascular wall permeability and changes in blood rheology. Abnormalities in microvascular structure and capillary density may also occur, affecting tissue material exchange and organ function."
        },
        {
          "sentence_id": "2",
          "sentence": "这种病理情况下，微循环结构及功能的异常导致其不能与组织和器官代谢水平相适应，影响组织的物质交换和器官功能状态称之为微循环障碍。",
          "start_idx": 210,
          "end_idx": 273,
          "entities": [
            {
              "entity_id": "T22",
              "entity": "微循环障碍",
              "entity_type": "Symptom",
              "start_idx": 57,
              "end_idx": 62,
              "entity_en": "Microcirculatory disorders"
            }
          ],
          "relations": [],
          "sentence_en": "Under this pathological condition, the abnormality of microcirculatory structure and function causes it to be unable to adapt to the metabolic levels of tissues and organs, affecting the material exchange of tissues and the functional status of organs, which is called microcirculatory disorder."
        }
      ],
      "paragraph_en": "2.1 Microcirculatory disorders Microcirculation is composed of arterioles, post-arterioles, precapillary sphincters, true capillaries, arteriovenous anastomoses and venules and the fluid flowing through them. It is the basic structure of the circulatory system and the main place and functional unit for the exchange of substances between blood and tissues. Under pathological conditions such as inflammatory reactions and metabolic disorders, vascular cell dysfunction, autonomic nervous dysfunction and endocrine hormone secretion disorders may occur, leading to microvascular vasomotor dysfunction, increased vascular wall permeability and changes in blood rheology, and abnormalities in microvascular structure and capillary density may occur, affecting tissue material exchange and organ function. Under such pathological conditions, the abnormality of microcirculatory structure and function leads to its inability to adapt to the metabolic level of tissues and organs, affecting tissue material exchange and organ function, which is called microcirculatory disorder."
    },
    {
      "paragraph_id": "5",
      "paragraph": "2.2 糖尿病微循环障碍由糖尿病相关因素导致的微循环障碍称之为糖尿病微循环障碍。它不仅在糖尿病血管并发症的发生中起着重要作用，而且参与了胰岛素抵抗及糖尿病的发生发展。目前糖尿病微循环障碍的确切发病机制尚未被完全阐明，主要涉及血管内皮受损及一氧化氮合成减少、多元醇通路激活、蛋白质非酶糖化、氧化应激、蛋白激酶C激活等多个方面的功能和代谢异常，进而出现微循环自律运动障碍，微血管血流量增加，压力增高。持续的血流动力学异常可致微血管结构损伤，通透性增加，毛细血管渗出，基底膜增厚，血管腔狭窄甚至闭塞，微血栓形成，发生微循环缺血、缺氧，进而导致器官功能障碍。微循环障碍可发生于糖尿病期及糖尿病前期，早期对其进行干预有助于糖尿病及其血管并发症的防治。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2.2 糖尿病微循环障碍由糖尿病相关因素导致的微循环障碍称之为糖尿病微循环障碍。它不仅在糖尿病血管并发症的发生中起着重要作用，而且参与了胰岛素抵抗及糖尿病的发生发展。目前糖尿病微循环障碍的确切发病机制尚未被完全阐明，主要涉及血管内皮受损及一氧化氮合成减少、多元醇通路激活、蛋白质非酶糖化、氧化应激、蛋白激酶C激活等多个方面的功能和代谢异常，进而出现微循环自律运动障碍，微血管血流量增加，压力增高。持续的血流动力学异常可致微血管结构损伤，通透性增加，毛细血管渗出，基底膜增厚，血管腔狭窄甚至闭塞，微血栓形成，发生微循环缺血、缺氧，进而导致器官功能障碍。微循环障碍可发生于糖尿病期及糖尿病前期，早期对其进行干预有助于糖尿病及其血管并发症的防治。",
          "start_idx": 0,
          "end_idx": 320,
          "entities": [
            {
              "entity_id": "T25",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 4,
              "end_idx": 7,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T26",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 13,
              "end_idx": 16,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T27",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 31,
              "end_idx": 34,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T28",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 44,
              "end_idx": 47,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T29",
              "entity": "胰岛素抵抗",
              "entity_type": "Disease",
              "start_idx": 68,
              "end_idx": 73,
              "entity_en": "Insulin resistance"
            },
            {
              "entity_id": "T30",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 74,
              "end_idx": 77,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T31",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 284,
              "end_idx": 287,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T32",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 289,
              "end_idx": 292,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T33",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 306,
              "end_idx": 309,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T34",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 85,
              "end_idx": 88,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T35",
              "entity": "微循环障碍",
              "entity_type": "Symptom",
              "start_idx": 7,
              "end_idx": 12,
              "entity_en": "Microcirculatory disorders"
            },
            {
              "entity_id": "T36",
              "entity": "微循环障碍",
              "entity_type": "Symptom",
              "start_idx": 23,
              "end_idx": 28,
              "entity_en": "Microcirculatory disorders"
            },
            {
              "entity_id": "T37",
              "entity": "微循环障碍",
              "entity_type": "Symptom",
              "start_idx": 34,
              "end_idx": 39,
              "entity_en": "Microcirculatory disorders"
            },
            {
              "entity_id": "T38",
              "entity": "微循环障碍",
              "entity_type": "Symptom",
              "start_idx": 88,
              "end_idx": 93,
              "entity_en": "Microcirculatory disorders"
            },
            {
              "entity_id": "T39",
              "entity": "微循环障碍",
              "entity_type": "Symptom",
              "start_idx": 275,
              "end_idx": 280,
              "entity_en": "Microcirculatory disorders"
            },
            {
              "entity_id": "T40",
              "entity": "血管内皮受损",
              "entity_type": "Pathogenesis",
              "start_idx": 112,
              "end_idx": 118,
              "entity_en": "Vascular endothelial damage"
            },
            {
              "entity_id": "T41",
              "entity": "一氧化氮合成减少",
              "entity_type": "Pathogenesis",
              "start_idx": 119,
              "end_idx": 127,
              "entity_en": "Decreased nitric oxide production"
            },
            {
              "entity_id": "T42",
              "entity": "多元醇通路激活",
              "entity_type": "Pathogenesis",
              "start_idx": 128,
              "end_idx": 135,
              "entity_en": "Polyol pathway activation"
            },
            {
              "entity_id": "T43",
              "entity": "蛋白质非酶糖化",
              "entity_type": "Pathogenesis",
              "start_idx": 136,
              "end_idx": 143,
              "entity_en": "Non-enzymatic glycation of proteins"
            },
            {
              "entity_id": "T44",
              "entity": "氧化应激",
              "entity_type": "Pathogenesis",
              "start_idx": 144,
              "end_idx": 148,
              "entity_en": "Oxidative stress"
            },
            {
              "entity_id": "T45",
              "entity": "蛋白激酶C激活",
              "entity_type": "Pathogenesis",
              "start_idx": 149,
              "end_idx": 156,
              "entity_en": "Protein kinase C activation"
            }
          ],
          "relations": [
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R8",
              "head_entity_id": "T35",
              "tail_entity_id": "T25"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R9",
              "head_entity_id": "T36",
              "tail_entity_id": "T26"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R10",
              "head_entity_id": "T37",
              "tail_entity_id": "T27"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R11",
              "head_entity_id": "T39",
              "tail_entity_id": "T31"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R12",
              "head_entity_id": "T39",
              "tail_entity_id": "T32"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R13",
              "head_entity_id": "T38",
              "tail_entity_id": "T34"
            },
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R14",
              "head_entity_id": "T40",
              "tail_entity_id": "T34"
            },
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R15",
              "head_entity_id": "T41",
              "tail_entity_id": "T34"
            },
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R16",
              "head_entity_id": "T42",
              "tail_entity_id": "T34"
            },
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R17",
              "head_entity_id": "T43",
              "tail_entity_id": "T34"
            },
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R18",
              "head_entity_id": "T44",
              "tail_entity_id": "T34"
            },
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R19",
              "head_entity_id": "T45",
              "tail_entity_id": "T34"
            }
          ],
          "sentence_en": "2.2 Diabetic microcirculatory disorders Microcirculatory disorders caused by diabetes-related factors are called diabetic microcirculatory disorders. It not only plays an important role in the occurrence of diabetic vascular complications, but also participates in the occurrence and development of insulin resistance and diabetes. At present, the exact pathogenesis of diabetic microcirculatory disorders has not been fully elucidated. It mainly involves functional and metabolic abnormalities in multiple aspects such as vascular endothelial damage and reduced nitric oxide synthesis, polyol pathway activation, protein non-enzymatic glycation, oxidative stress, and protein kinase C activation, which lead to microcirculatory autonomic movement disorders, increased microvascular blood flow, and increased pressure. Continuous hemodynamic abnormalities can cause microvascular structural damage, increased permeability, capillary exudation, basement membrane thickening, vascular lumen stenosis or even occlusion, microthrombosis, microcirculatory ischemia and hypoxia, and then lead to organ dysfunction. Microcirculatory disorders can occur in the diabetic and prediabetic stages. Early intervention is helpful for the prevention and treatment of diabetes and its vascular complications."
        }
      ],
      "paragraph_en": "2.2 Diabetic microcirculatory disorders Microcirculatory disorders caused by diabetes-related factors are called diabetic microcirculatory disorders. It not only plays an important role in the occurrence of diabetic vascular complications, but also participates in the occurrence and development of insulin resistance and diabetes. At present, the exact pathogenesis of diabetic microcirculatory disorders has not been fully elucidated. It mainly involves functional and metabolic abnormalities in multiple aspects such as vascular endothelial damage and reduced nitric oxide synthesis, polyol pathway activation, protein non-enzymatic glycation, oxidative stress, and protein kinase C activation, which lead to microcirculatory autonomic movement disorders, increased microvascular blood flow, and increased pressure. Continuous hemodynamic abnormalities can cause microvascular structural damage, increased permeability, capillary exudation, basement membrane thickening, vascular lumen stenosis or even occlusion, microthrombosis, microcirculatory ischemia and hypoxia, and then lead to organ dysfunction. Microcirculatory disorders can occur in the diabetic and prediabetic stages. Early intervention is helpful for the prevention and treatment of diabetes and its vascular complications."
    },
    {
      "paragraph_id": "6",
      "paragraph": "3 糖尿病微循环障碍的表现",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3 糖尿病微循环障碍的表现",
          "start_idx": 0,
          "end_idx": 13,
          "entities": [
            {
              "entity_id": "T46",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 5,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T47",
              "entity": "微循环障碍",
              "entity_type": "Symptom",
              "start_idx": 5,
              "end_idx": 10,
              "entity_en": "Microcirculatory disorders"
            }
          ],
          "relations": [
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R20",
              "head_entity_id": "T47",
              "tail_entity_id": "T46"
            }
          ],
          "sentence_en": "3. Manifestations of diabetic microcirculatory disorders"
        }
      ],
      "paragraph_en": "3. Manifestations of diabetic microcirculatory disorders"
    },
    {
      "paragraph_id": "7",
      "paragraph": "糖尿病微循环障碍在糖尿病肾病、糖尿病视网膜病变、糖尿病神经病变和糖尿病足病的发生发展中发挥着重要作用，是这些糖尿病慢性并发症共同的病因学机制之一。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "糖尿病微循环障碍在糖尿病肾病、糖尿病视网膜病变、糖尿病神经病变和糖尿病足病的发生发展中发挥着重要作用，是这些糖尿病慢性并发症共同的病因学机制之一。",
          "start_idx": 0,
          "end_idx": 73,
          "entities": [
            {
              "entity_id": "T48",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 9,
              "end_idx": 14,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T49",
              "entity": "糖尿病视网膜病变",
              "entity_type": "Disease",
              "start_idx": 15,
              "end_idx": 23,
              "entity_en": "Diabetic retinopathy"
            },
            {
              "entity_id": "T50",
              "entity": "糖尿病神经病变",
              "entity_type": "Disease",
              "start_idx": 24,
              "end_idx": 31,
              "entity_en": "Diabetic neuropathy"
            },
            {
              "entity_id": "T51",
              "entity": "糖尿病足病",
              "entity_type": "Disease",
              "start_idx": 32,
              "end_idx": 37,
              "entity_en": "Diabetic foot disease"
            },
            {
              "entity_id": "T52",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 12,
              "end_idx": 13,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T53",
              "entity": "视网膜",
              "entity_type": "Anatomy",
              "start_idx": 18,
              "end_idx": 21,
              "entity_en": "Retina"
            },
            {
              "entity_id": "T54",
              "entity": "足",
              "entity_type": "Anatomy",
              "start_idx": 35,
              "end_idx": 36,
              "entity_en": "foot"
            },
            {
              "entity_id": "T55",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 3,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T56",
              "entity": "微循环障碍",
              "entity_type": "Symptom",
              "start_idx": 3,
              "end_idx": 8,
              "entity_en": "Microcirculatory disorders"
            },
            {
              "entity_id": "T57",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 54,
              "end_idx": 57,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T58",
              "entity": "神经",
              "entity_type": "Anatomy",
              "start_idx": 27,
              "end_idx": 29,
              "entity_en": "nerve"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R21",
              "head_entity_id": "T52",
              "tail_entity_id": "T48"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R22",
              "head_entity_id": "T53",
              "tail_entity_id": "T49"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R23",
              "head_entity_id": "T58",
              "tail_entity_id": "T50"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R24",
              "head_entity_id": "T54",
              "tail_entity_id": "T51"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R25",
              "head_entity_id": "T56",
              "tail_entity_id": "T55"
            }
          ],
          "sentence_en": "Diabetic microcirculatory disorders play an important role in the occurrence and development of diabetic nephropathy, diabetic retinopathy, diabetic neuropathy and diabetic foot disease, and are one of the common etiological mechanisms of these chronic complications of diabetes."
        }
      ],
      "paragraph_en": "Diabetic microcirculatory disorders play an important role in the occurrence and development of diabetic nephropathy, diabetic retinopathy, diabetic neuropathy and diabetic foot disease, and are one of the common etiological mechanisms of these chronic complications of diabetes."
    },
    {
      "paragraph_id": "8",
      "paragraph": "3.1 糖尿病肾病糖尿病肾病的主要病理改变表现为肾小球基底膜增厚、肾小球系膜区细胞外基质沉积，最终肾小球硬化伴或不伴肾小管间质纤维化。肾小球受累临床主要表现为进行性肾小球滤过率降低和尿白蛋白排泄增多。随着病程的进展出现严重肾小球硬化时，肾脏会逐步缩小。微量白蛋白尿是糖尿病肾病的早期临床表现，也是诊断糖尿病肾病的重要依据。糖尿病肾病自然病程分为5期：急性肾小球高滤过期、正常白蛋白尿期(尿蛋白排泄正常或间歇性白蛋白尿)、早期糖尿病肾病期(持续微量白蛋白尿)、临床糖尿病肾病期(显性白蛋白尿，部分进展为肾病综合征)、肾衰竭期。糖尿病肾病是糖尿病患者肾功能衰竭的主要原因。糖尿病肾病最新进展研究表明，肾小管损伤也应包括在糖尿病肾病概念中，其在疾病的早期即可出现，且可先于肾小球病变。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3.1 糖尿病肾病糖尿病肾病的主要病理改变表现为肾小球基底膜增厚、肾小球系膜区细胞外基质沉积，最终肾小球硬化伴或不伴肾小管间质纤维化。肾小球受累临床主要表现为进行性肾小球滤过率降低和尿白蛋白排泄增多。随着病程的进展出现严重肾小球硬化时，肾脏会逐步缩小。微量白蛋白尿是糖尿病肾病的早期临床表现，也是诊断糖尿病肾病的重要依据。糖尿病肾病自然病程分为5期：急性肾小球高滤过期、正常白蛋白尿期(尿蛋白排泄正常或间歇性白蛋白尿)、早期糖尿病肾病期(持续微量白蛋白尿)、临床糖尿病肾病期(显性白蛋白尿，部分进展为肾病综合征)、肾衰竭期。糖尿病肾病是糖尿病患者肾功能衰竭的主要原因。糖尿病肾病最新进展研究表明，肾小管损伤也应包括在糖尿病肾病概念中，其在疾病的早期即可出现，且可先于肾小球病变。",
          "start_idx": 0,
          "end_idx": 339,
          "entities": [
            {
              "entity_id": "T59",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 4,
              "end_idx": 9,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T60",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 9,
              "end_idx": 14,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T61",
              "entity": "肾小球硬化",
              "entity_type": "Disease",
              "start_idx": 49,
              "end_idx": 54,
              "entity_en": "Glomerulosclerosis"
            },
            {
              "entity_id": "T62",
              "entity": "肾小管间质纤维化",
              "entity_type": "Disease",
              "start_idx": 58,
              "end_idx": 66,
              "entity_en": "Tubulointerstitial fibrosis"
            },
            {
              "entity_id": "T63",
              "entity": "肾小球硬化",
              "entity_type": "Disease",
              "start_idx": 111,
              "end_idx": 116,
              "entity_en": "Glomerulosclerosis"
            },
            {
              "entity_id": "T64",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 133,
              "end_idx": 138,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T65",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 150,
              "end_idx": 155,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T66",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 161,
              "end_idx": 166,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T67",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 262,
              "end_idx": 267,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T68",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 268,
              "end_idx": 271,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T69",
              "entity": "肾功能衰竭",
              "entity_type": "Disease",
              "start_idx": 273,
              "end_idx": 278,
              "entity_en": "Renal failure"
            },
            {
              "entity_id": "T70",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 284,
              "end_idx": 289,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T71",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 308,
              "end_idx": 313,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T72",
              "entity": "肾小球基底膜增厚",
              "entity_type": "Symptom",
              "start_idx": 24,
              "end_idx": 32,
              "entity_en": "Glomerular basement membrane thickening"
            },
            {
              "entity_id": "T73",
              "entity": "肾小球系膜区细胞外基质沉积",
              "entity_type": "Symptom",
              "start_idx": 33,
              "end_idx": 46,
              "entity_en": "Extracellular matrix deposition in the glomerular mesangium"
            },
            {
              "entity_id": "T74",
              "entity": "进行性肾小球滤过率降低",
              "entity_type": "Symptom",
              "start_idx": 79,
              "end_idx": 90,
              "entity_en": "Progressive decrease in glomerular filtration rate"
            },
            {
              "entity_id": "T75",
              "entity": "尿白蛋白排泄增多",
              "entity_type": "Symptom",
              "start_idx": 91,
              "end_idx": 99,
              "entity_en": "Increased urinary albumin excretion"
            },
            {
              "entity_id": "T76",
              "entity": "肾脏会逐步缩小",
              "entity_type": "Symptom",
              "start_idx": 118,
              "end_idx": 125,
              "entity_en": "The kidneys gradually shrink"
            },
            {
              "entity_id": "T77",
              "entity": "微量白蛋白尿",
              "entity_type": "Symptom",
              "start_idx": 126,
              "end_idx": 132,
              "entity_en": "Microalbuminuria"
            },
            {
              "entity_id": "T78",
              "entity": "肾小管损伤",
              "entity_type": "Symptom",
              "start_idx": 298,
              "end_idx": 303,
              "entity_en": "Renal tubular damage"
            },
            {
              "entity_id": "T79",
              "entity": "肾小球病变",
              "entity_type": "Symptom",
              "start_idx": 333,
              "end_idx": 338,
              "entity_en": "Glomerular lesions"
            },
            {
              "entity_id": "T80",
              "entity": "急性肾小球高滤过期",
              "entity_type": "Class",
              "start_idx": 175,
              "end_idx": 184,
              "entity_en": "Acute glomerular hyperfiltration phase"
            },
            {
              "entity_id": "T81",
              "entity": "正常白蛋白尿期",
              "entity_type": "Class",
              "start_idx": 185,
              "end_idx": 192,
              "entity_en": "Normoalbuminuria"
            },
            {
              "entity_id": "T82",
              "entity": "早期糖尿病肾病期",
              "entity_type": "Class",
              "start_idx": 210,
              "end_idx": 218,
              "entity_en": "Early diabetic nephropathy"
            },
            {
              "entity_id": "T83",
              "entity": "临床糖尿病肾病期",
              "entity_type": "Class",
              "start_idx": 229,
              "end_idx": 237,
              "entity_en": "Clinical diabetic nephropathy"
            },
            {
              "entity_id": "T84",
              "entity": "肾衰竭期",
              "entity_type": "Class",
              "start_idx": 257,
              "end_idx": 261,
              "entity_en": "Renal failure"
            },
            {
              "entity_id": "T85",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 7,
              "end_idx": 8,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T86",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 12,
              "end_idx": 13,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T87",
              "entity": "肾小球",
              "entity_type": "Anatomy",
              "start_idx": 49,
              "end_idx": 52,
              "entity_en": "Glomerulus"
            },
            {
              "entity_id": "T88",
              "entity": "肾小管",
              "entity_type": "Anatomy",
              "start_idx": 58,
              "end_idx": 61,
              "entity_en": "Renal tubules"
            },
            {
              "entity_id": "T89",
              "entity": "肾小球",
              "entity_type": "Anatomy",
              "start_idx": 111,
              "end_idx": 114,
              "entity_en": "Glomerulus"
            },
            {
              "entity_id": "T90",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 153,
              "end_idx": 154,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T91",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 136,
              "end_idx": 137,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T92",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 164,
              "end_idx": 165,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T93",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 265,
              "end_idx": 266,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T94",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 273,
              "end_idx": 274,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T95",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 287,
              "end_idx": 288,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T96",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 311,
              "end_idx": 312,
              "entity_en": "kidney"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R26",
              "head_entity_id": "T85",
              "tail_entity_id": "T59"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R27",
              "head_entity_id": "T86",
              "tail_entity_id": "T60"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R28",
              "head_entity_id": "T72",
              "tail_entity_id": "T60"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R29",
              "head_entity_id": "T73",
              "tail_entity_id": "T60"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R30",
              "head_entity_id": "T88",
              "tail_entity_id": "T62"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R31",
              "head_entity_id": "T89",
              "tail_entity_id": "T63"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R32",
              "head_entity_id": "T76",
              "tail_entity_id": "T63"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R33",
              "head_entity_id": "T91",
              "tail_entity_id": "T64"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R34",
              "head_entity_id": "T77",
              "tail_entity_id": "T64"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R35",
              "head_entity_id": "T90",
              "tail_entity_id": "T65"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R36",
              "head_entity_id": "T92",
              "tail_entity_id": "T66"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R37",
              "head_entity_id": "T80",
              "tail_entity_id": "T66"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R38",
              "head_entity_id": "T81",
              "tail_entity_id": "T66"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R39",
              "head_entity_id": "T82",
              "tail_entity_id": "T66"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R40",
              "head_entity_id": "T83",
              "tail_entity_id": "T66"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R41",
              "head_entity_id": "T84",
              "tail_entity_id": "T66"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R42",
              "head_entity_id": "T93",
              "tail_entity_id": "T67"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R43",
              "head_entity_id": "T94",
              "tail_entity_id": "T69"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R44",
              "head_entity_id": "T95",
              "tail_entity_id": "T70"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R45",
              "head_entity_id": "T96",
              "tail_entity_id": "T71"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R46",
              "head_entity_id": "T78",
              "tail_entity_id": "T71"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R47",
              "head_entity_id": "T79",
              "tail_entity_id": "T71"
            }
          ],
          "sentence_en": "3.1 Diabetic nephropathy The main pathological changes of diabetic nephropathy are thickening of the glomerular basement membrane, deposition of extracellular matrix in the glomerular mesangial area, and eventually glomerular sclerosis with or without tubulointerstitial fibrosis. The clinical manifestations of glomerular involvement are mainly progressive decrease in glomerular filtration rate and increased urinary albumin excretion. As the disease progresses, when severe glomerular sclerosis occurs, the kidneys will gradually shrink. Microalbuminuria is an early clinical manifestation of diabetic nephropathy and an important basis for diagnosing diabetic nephropathy. The natural course of diabetic nephropathy is divided into five stages: acute glomerular hyperfiltration stage, normal albuminuria stage (normal urinary protein excretion or intermittent albuminuria), early diabetic nephropathy stage (persistent microalbuminuria), clinical diabetic nephropathy stage (overt albuminuria, some progress to nephrotic syndrome), and renal failure stage. Diabetic nephropathy is the main cause of renal failure in diabetic patients. The latest progress in diabetic nephropathy shows that tubular damage should also be included in the concept of diabetic nephropathy, which can appear in the early stage of the disease and may precede glomerular lesions."
        }
      ],
      "paragraph_en": "3.1 Diabetic nephropathy The main pathological changes of diabetic nephropathy are thickening of the glomerular basement membrane, deposition of extracellular matrix in the glomerular mesangial area, and eventually glomerular sclerosis with or without tubulointerstitial fibrosis. The clinical manifestations of glomerular involvement are mainly progressive decrease in glomerular filtration rate and increased urinary albumin excretion. As the disease progresses, when severe glomerular sclerosis occurs, the kidneys will gradually shrink. Microalbuminuria is an early clinical manifestation of diabetic nephropathy and an important basis for diagnosing diabetic nephropathy. The natural course of diabetic nephropathy is divided into five stages: acute glomerular hyperfiltration stage, normal albuminuria stage (normal urinary protein excretion or intermittent albuminuria), early diabetic nephropathy stage (persistent microalbuminuria), clinical diabetic nephropathy stage (overt albuminuria, some progress to nephrotic syndrome), and renal failure stage. Diabetic nephropathy is the main cause of renal failure in diabetic patients. The latest progress in diabetic nephropathy shows that tubular damage should also be included in the concept of diabetic nephropathy, which can appear in the early stage of the disease and may precede glomerular lesions."
    },
    {
      "paragraph_id": "9",
      "paragraph": "3.2 糖尿病视网膜病变糖尿病视网膜病变的病理特征是周细胞丢失、视神经视网膜异常和血管新生。糖尿病视网膜病变的主要临床表现为微血管瘤、出血斑点、硬性渗出、棉绒斑、静脉串珠状、视网膜内微血管异常(intraretinal microvascular abnormality，IRMA)以及黄斑水肿等。广泛出血会引起视网膜或视盘的新生血管、视网膜前出血、玻璃体积血及牵拉性视网膜脱离，微血管瘤出现最早期。糖尿病视网膜病变临床表现分为6期(具体分型、分期标准参考相关指南)。糖尿病视网膜病变是导致糖尿病患者失明的主要原因。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3.2 糖尿病视网膜病变糖尿病视网膜病变的病理特征是周细胞丢失、视神经视网膜异常和血管新生。糖尿病视网膜病变的主要临床表现为微血管瘤、出血斑点、硬性渗出、棉绒斑、静脉串珠状、视网膜内微血管异常(intraretinal microvascular abnormality，IRMA)以及黄斑水肿等。广泛出血会引起视网膜或视盘的新生血管、视网膜前出血、玻璃体积血及牵拉性视网膜脱离，微血管瘤出现最早期。",
          "start_idx": 0,
          "end_idx": 200,
          "entities": [
            {
              "entity_id": "T97",
              "entity": "糖尿病视网膜病变",
              "entity_type": "Disease",
              "start_idx": 4,
              "end_idx": 12,
              "entity_en": "Diabetic retinopathy"
            },
            {
              "entity_id": "T98",
              "entity": "糖尿病视网膜病变",
              "entity_type": "Disease",
              "start_idx": 12,
              "end_idx": 20,
              "entity_en": "Diabetic retinopathy"
            },
            {
              "entity_id": "T99",
              "entity": "糖尿病视网膜病变",
              "entity_type": "Disease",
              "start_idx": 46,
              "end_idx": 54,
              "entity_en": "Diabetic retinopathy"
            },
            {
              "entity_id": "T100",
              "entity": "视网膜或视盘的新生血管",
              "entity_type": "Disease",
              "start_idx": 156,
              "end_idx": 167,
              "entity_en": "Neovascularization of the retina or optic disc"
            },
            {
              "entity_id": "T101",
              "entity": "视网膜前出血",
              "entity_type": "Disease",
              "start_idx": 168,
              "end_idx": 174,
              "entity_en": "Preretinal hemorrhage"
            },
            {
              "entity_id": "T102",
              "entity": "玻璃体积血",
              "entity_type": "Disease",
              "start_idx": 175,
              "end_idx": 180,
              "entity_en": "Vitreous hemorrhage"
            },
            {
              "entity_id": "T103",
              "entity": "牵拉性视网膜脱离",
              "entity_type": "Disease",
              "start_idx": 181,
              "end_idx": 189,
              "entity_en": "Tractional retinal detachment"
            },
            {
              "entity_id": "T104",
              "entity": "微血管瘤",
              "entity_type": "Disease",
              "start_idx": 190,
              "end_idx": 194,
              "entity_en": "Microaneurysm"
            },
            {
              "entity_id": "T109",
              "entity": "视网膜",
              "entity_type": "Anatomy",
              "start_idx": 7,
              "end_idx": 10,
              "entity_en": "Retina"
            },
            {
              "entity_id": "T110",
              "entity": "视网膜",
              "entity_type": "Anatomy",
              "start_idx": 15,
              "end_idx": 18,
              "entity_en": "Retina"
            },
            {
              "entity_id": "T111",
              "entity": "视网膜",
              "entity_type": "Anatomy",
              "start_idx": 49,
              "end_idx": 52,
              "entity_en": "Retina"
            },
            {
              "entity_id": "T112",
              "entity": "视网膜",
              "entity_type": "Anatomy",
              "start_idx": 156,
              "end_idx": 159,
              "entity_en": "Retina"
            },
            {
              "entity_id": "T113",
              "entity": "视盘",
              "entity_type": "Anatomy",
              "start_idx": 160,
              "end_idx": 162,
              "entity_en": "Video disc"
            },
            {
              "entity_id": "T114",
              "entity": "视网膜",
              "entity_type": "Anatomy",
              "start_idx": 168,
              "end_idx": 171,
              "entity_en": "Retina"
            },
            {
              "entity_id": "T115",
              "entity": "玻璃体",
              "entity_type": "Anatomy",
              "start_idx": 175,
              "end_idx": 178,
              "entity_en": "Vitreous"
            },
            {
              "entity_id": "T116",
              "entity": "视网膜",
              "entity_type": "Anatomy",
              "start_idx": 184,
              "end_idx": 187,
              "entity_en": "Retina"
            },
            {
              "entity_id": "T119",
              "entity": "周细胞丢失",
              "entity_type": "Symptom",
              "start_idx": 26,
              "end_idx": 31,
              "entity_en": "Pericyte loss"
            },
            {
              "entity_id": "T120",
              "entity": "视神经视网膜异常",
              "entity_type": "Symptom",
              "start_idx": 32,
              "end_idx": 40,
              "entity_en": "Neuroretinal abnormalities"
            },
            {
              "entity_id": "T121",
              "entity": "血管新生",
              "entity_type": "Symptom",
              "start_idx": 41,
              "end_idx": 45,
              "entity_en": "Angiogenesis"
            },
            {
              "entity_id": "T122",
              "entity": "微血管瘤",
              "entity_type": "Symptom",
              "start_idx": 62,
              "end_idx": 66,
              "entity_en": "Microaneurysm"
            },
            {
              "entity_id": "T123",
              "entity": "出血斑点",
              "entity_type": "Symptom",
              "start_idx": 67,
              "end_idx": 71,
              "entity_en": "Bleeding spots"
            },
            {
              "entity_id": "T124",
              "entity": "硬性渗出",
              "entity_type": "Symptom",
              "start_idx": 72,
              "end_idx": 76,
              "entity_en": "Hard exudate"
            },
            {
              "entity_id": "T125",
              "entity": "棉绒斑",
              "entity_type": "Symptom",
              "start_idx": 77,
              "end_idx": 80,
              "entity_en": "Cotton-wool spots"
            },
            {
              "entity_id": "T126",
              "entity": "静脉串珠状",
              "entity_type": "Symptom",
              "start_idx": 81,
              "end_idx": 86,
              "entity_en": "Venous beading"
            },
            {
              "entity_id": "T127",
              "entity": "视网膜内微血管异常(intraretinal microvascular abnormality，IRMA)",
              "entity_type": "Symptom",
              "start_idx": 87,
              "end_idx": 141,
              "entity_en": "Intraretinal microvascular abnormality (IRMA)"
            },
            {
              "entity_id": "T128",
              "entity": "黄斑水肿",
              "entity_type": "Symptom",
              "start_idx": 143,
              "end_idx": 147,
              "entity_en": "Macular edema"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R48",
              "head_entity_id": "T109",
              "tail_entity_id": "T97"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R49",
              "head_entity_id": "T110",
              "tail_entity_id": "T98"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R50",
              "head_entity_id": "T119",
              "tail_entity_id": "T98"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R51",
              "head_entity_id": "T120",
              "tail_entity_id": "T98"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R52",
              "head_entity_id": "T121",
              "tail_entity_id": "T98"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R53",
              "head_entity_id": "T111",
              "tail_entity_id": "T99"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R54",
              "head_entity_id": "T122",
              "tail_entity_id": "T99"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R55",
              "head_entity_id": "T123",
              "tail_entity_id": "T99"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R56",
              "head_entity_id": "T124",
              "tail_entity_id": "T99"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R57",
              "head_entity_id": "T125",
              "tail_entity_id": "T99"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R58",
              "head_entity_id": "T126",
              "tail_entity_id": "T99"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R59",
              "head_entity_id": "T127",
              "tail_entity_id": "T99"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R60",
              "head_entity_id": "T128",
              "tail_entity_id": "T99"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R61",
              "head_entity_id": "T112",
              "tail_entity_id": "T100"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R62",
              "head_entity_id": "T113",
              "tail_entity_id": "T100"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R63",
              "head_entity_id": "T114",
              "tail_entity_id": "T101"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R64",
              "head_entity_id": "T115",
              "tail_entity_id": "T102"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R65",
              "head_entity_id": "T116",
              "tail_entity_id": "T103"
            }
          ],
          "sentence_en": "3.2 Diabetic retinopathy The pathological characteristics of diabetic retinopathy are pericyte loss, optic nerve retinal abnormalities and angiogenesis. The main clinical manifestations of diabetic retinopathy are microaneurysms, hemorrhagic spots, hard exudates, cotton wool spots, venous beading, intraretinal microvascular abnormality (IRMA) and macular edema. Extensive hemorrhage can cause neovascularization of the retina or optic disc, preretinal hemorrhage, vitreous hemorrhage and tractional retinal detachment, with microaneurysms appearing in the earliest stage."
        },
        {
          "sentence_id": "1",
          "sentence": "糖尿病视网膜病变临床表现分为6期(具体分型、分期标准参考相关指南)。",
          "start_idx": 200,
          "end_idx": 234,
          "entities": [
            {
              "entity_id": "T105",
              "entity": "糖尿病视网膜病变",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 8,
              "entity_en": "Diabetic retinopathy"
            },
            {
              "entity_id": "T117",
              "entity": "视网膜",
              "entity_type": "Anatomy",
              "start_idx": 3,
              "end_idx": 6,
              "entity_en": "Retina"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R66",
              "head_entity_id": "T117",
              "tail_entity_id": "T105"
            }
          ],
          "sentence_en": "The clinical manifestations of diabetic retinopathy are divided into 6 stages (please refer to relevant guidelines for specific classification and staging standards)."
        },
        {
          "sentence_id": "2",
          "sentence": "糖尿病视网膜病变是导致糖尿病患者失明的主要原因。",
          "start_idx": 234,
          "end_idx": 258,
          "entities": [
            {
              "entity_id": "T106",
              "entity": "糖尿病视网膜病变",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 8,
              "entity_en": "Diabetic retinopathy"
            },
            {
              "entity_id": "T107",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 11,
              "end_idx": 14,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T108",
              "entity": "失明",
              "entity_type": "Disease",
              "start_idx": 16,
              "end_idx": 18,
              "entity_en": "blindness"
            },
            {
              "entity_id": "T118",
              "entity": "视网膜",
              "entity_type": "Anatomy",
              "start_idx": 3,
              "end_idx": 6,
              "entity_en": "Retina"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R67",
              "head_entity_id": "T118",
              "tail_entity_id": "T106"
            }
          ],
          "sentence_en": "Diabetic retinopathy is the leading cause of blindness in people with diabetes."
        }
      ],
      "paragraph_en": "3.2 Diabetic retinopathy The pathological characteristics of diabetic retinopathy are pericyte loss, optic nerve and retinal abnormalities, and angiogenesis. The main clinical manifestations of diabetic retinopathy are microaneurysms, hemorrhagic spots, hard exudates, cotton wool spots, venous beading, intraretinal microvascular abnormalities (IRMA), and macular edema. Extensive hemorrhage can cause neovascularization of the retina or optic disc, preretinal hemorrhage, vitreous hemorrhage, and tractional retinal detachment, with microaneurysms appearing in the earliest stage. The clinical manifestations of diabetic retinopathy are divided into 6 stages (refer to relevant guidelines for specific classification and staging standards). Diabetic retinopathy is the main cause of blindness in diabetic patients."
    },
    {
      "paragraph_id": "10",
      "paragraph": "3.3 糖尿病神经病变糖尿病神经病变主要可累及周围神经、自主神经、颅神经，脑及脊髓也可受累，早期表现为神经纤维脱髓鞘和轴突变性、Schwann细胞增生。随着病程进展，表现为轴突变性和髓鞘纤维消失。周围神经病变最常见的症状，诸如麻木、疼痛等感觉异常或者感觉丧失。自主神经受累时，可表现为心血管、胃肠道、泌尿生殖系统和排汗障碍或失调。颅神经病变以动眼神经受损最常见，其次为外展神经、滑车神经、面神经和三叉神经等，常单侧受累，双侧受累少见。脊髓病变以后索损害为主，主要为变性改变。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3.3 糖尿病神经病变糖尿病神经病变主要可累及周围神经、自主神经、颅神经，脑及脊髓也可受累，早期表现为神经纤维脱髓鞘和轴突变性、Schwann细胞增生。随着病程进展，表现为轴突变性和髓鞘纤维消失。周围神经病变最常见的症状，诸如麻木、疼痛等感觉异常或者感觉丧失。自主神经受累时，可表现为心血管、胃肠道、泌尿生殖系统和排汗障碍或失调。颅神经病变以动眼神经受损最常见，其次为外展神经、滑车神经、面神经和三叉神经等，常单侧受累，双侧受累少见。脊髓病变以后索损害为主，主要为变性改变。",
          "start_idx": 0,
          "end_idx": 237,
          "entities": [
            {
              "entity_id": "T129",
              "entity": "糖尿病神经病变",
              "entity_type": "Disease",
              "start_idx": 4,
              "end_idx": 11,
              "entity_en": "Diabetic neuropathy"
            },
            {
              "entity_id": "T130",
              "entity": "糖尿病神经病变",
              "entity_type": "Disease",
              "start_idx": 11,
              "end_idx": 18,
              "entity_en": "Diabetic neuropathy"
            },
            {
              "entity_id": "T131",
              "entity": "神经",
              "entity_type": "Anatomy",
              "start_idx": 7,
              "end_idx": 9,
              "entity_en": "nerve"
            },
            {
              "entity_id": "T132",
              "entity": "神经",
              "entity_type": "Anatomy",
              "start_idx": 14,
              "end_idx": 16,
              "entity_en": "nerve"
            },
            {
              "entity_id": "T133",
              "entity": "周围神经",
              "entity_type": "Anatomy",
              "start_idx": 23,
              "end_idx": 27,
              "entity_en": "Peripheral nerves"
            },
            {
              "entity_id": "T134",
              "entity": "自主神经",
              "entity_type": "Anatomy",
              "start_idx": 28,
              "end_idx": 32,
              "entity_en": "Autonomic nerves"
            },
            {
              "entity_id": "T135",
              "entity": "颅神经",
              "entity_type": "Anatomy",
              "start_idx": 33,
              "end_idx": 36,
              "entity_en": "Cranial nerves"
            },
            {
              "entity_id": "T136",
              "entity": "脑",
              "entity_type": "Anatomy",
              "start_idx": 37,
              "end_idx": 38,
              "entity_en": "brain"
            },
            {
              "entity_id": "T137",
              "entity": "脊髓",
              "entity_type": "Anatomy",
              "start_idx": 39,
              "end_idx": 41,
              "entity_en": "spinal cord"
            },
            {
              "entity_id": "T138",
              "entity": "神经纤维脱髓鞘",
              "entity_type": "Symptom",
              "start_idx": 51,
              "end_idx": 58,
              "entity_en": "Demyelination of nerve fibers"
            },
            {
              "entity_id": "T139",
              "entity": "轴突变性",
              "entity_type": "Symptom",
              "start_idx": 59,
              "end_idx": 63,
              "entity_en": "Axonal degeneration"
            },
            {
              "entity_id": "T140",
              "entity": "Schwann细胞增生",
              "entity_type": "Symptom",
              "start_idx": 64,
              "end_idx": 75,
              "entity_en": "Schwann cell proliferation"
            },
            {
              "entity_id": "T141",
              "entity": "轴突变性",
              "entity_type": "Symptom",
              "start_idx": 86,
              "end_idx": 90,
              "entity_en": "Axonal degeneration"
            },
            {
              "entity_id": "T142",
              "entity": "髓鞘纤维消失",
              "entity_type": "Symptom",
              "start_idx": 91,
              "end_idx": 97,
              "entity_en": "Loss of myelin fibers"
            },
            {
              "entity_id": "T143",
              "entity": "周围神经病变",
              "entity_type": "Disease",
              "start_idx": 98,
              "end_idx": 104,
              "entity_en": "Peripheral neuropathy"
            },
            {
              "entity_id": "T144",
              "entity": "麻木",
              "entity_type": "Symptom",
              "start_idx": 113,
              "end_idx": 115,
              "entity_en": "numbness"
            },
            {
              "entity_id": "T145",
              "entity": "疼痛",
              "entity_type": "Symptom",
              "start_idx": 116,
              "end_idx": 118,
              "entity_en": "pain"
            },
            {
              "entity_id": "T146",
              "entity": "感觉异常",
              "entity_type": "Symptom",
              "start_idx": 119,
              "end_idx": 123,
              "entity_en": "Paresthesias"
            },
            {
              "entity_id": "T147",
              "entity": "感觉丧失",
              "entity_type": "Symptom",
              "start_idx": 125,
              "end_idx": 129,
              "entity_en": "Loss of sensation"
            },
            {
              "entity_id": "T148",
              "entity": "自主神经受累",
              "entity_type": "Symptom",
              "start_idx": 130,
              "end_idx": 136,
              "entity_en": "Autonomic nerve involvement"
            },
            {
              "entity_id": "T149",
              "entity": "心血管、胃肠道、泌尿生殖系统和排汗障碍或失调",
              "entity_type": "Symptom",
              "start_idx": 142,
              "end_idx": 164,
              "entity_en": "Cardiovascular, gastrointestinal, genitourinary, and sweating disorders or disturbances"
            },
            {
              "entity_id": "T150",
              "entity": "颅神经病变",
              "entity_type": "Disease",
              "start_idx": 165,
              "end_idx": 170,
              "entity_en": "Cranial Neuropathy"
            },
            {
              "entity_id": "T151",
              "entity": "颅神经",
              "entity_type": "Anatomy",
              "start_idx": 165,
              "end_idx": 168,
              "entity_en": "Cranial nerves"
            },
            {
              "entity_id": "T152",
              "entity": "眼神经受损",
              "entity_type": "Symptom",
              "start_idx": 172,
              "end_idx": 177,
              "entity_en": "Damage to the optic nerve"
            },
            {
              "entity_id": "T153",
              "entity": "外展神经",
              "entity_type": "Anatomy",
              "start_idx": 184,
              "end_idx": 188,
              "entity_en": "Abducens nerve"
            },
            {
              "entity_id": "T154",
              "entity": "滑车神经",
              "entity_type": "Anatomy",
              "start_idx": 189,
              "end_idx": 193,
              "entity_en": "Trochlear nerve"
            },
            {
              "entity_id": "T155",
              "entity": "面神经",
              "entity_type": "Anatomy",
              "start_idx": 194,
              "end_idx": 197,
              "entity_en": "Facial nerve"
            },
            {
              "entity_id": "T156",
              "entity": "三叉神经",
              "entity_type": "Anatomy",
              "start_idx": 198,
              "end_idx": 202,
              "entity_en": "Trigeminal nerve"
            },
            {
              "entity_id": "T157",
              "entity": "脊髓病变",
              "entity_type": "Disease",
              "start_idx": 217,
              "end_idx": 221,
              "entity_en": "Spinal cord lesions"
            },
            {
              "entity_id": "T158",
              "entity": "脊髓",
              "entity_type": "Anatomy",
              "start_idx": 217,
              "end_idx": 219,
              "entity_en": "spinal cord"
            },
            {
              "entity_id": "T159",
              "entity": "后索损害",
              "entity_type": "Symptom",
              "start_idx": 222,
              "end_idx": 226,
              "entity_en": "Rear cable damage"
            },
            {
              "entity_id": "T160",
              "entity": "变性改变",
              "entity_type": "Symptom",
              "start_idx": 232,
              "end_idx": 236,
              "entity_en": "Degeneration"
            },
            {
              "entity_id": "T161",
              "entity": "周围神经",
              "entity_type": "Anatomy",
              "start_idx": 98,
              "end_idx": 102,
              "entity_en": "Peripheral nerves"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R68",
              "head_entity_id": "T131",
              "tail_entity_id": "T129"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R69",
              "head_entity_id": "T132",
              "tail_entity_id": "T130"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R70",
              "head_entity_id": "T133",
              "tail_entity_id": "T130"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R71",
              "head_entity_id": "T134",
              "tail_entity_id": "T130"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R72",
              "head_entity_id": "T135",
              "tail_entity_id": "T130"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R73",
              "head_entity_id": "T136",
              "tail_entity_id": "T130"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R74",
              "head_entity_id": "T137",
              "tail_entity_id": "T130"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R75",
              "head_entity_id": "T138",
              "tail_entity_id": "T130"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R76",
              "head_entity_id": "T139",
              "tail_entity_id": "T130"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R77",
              "head_entity_id": "T140",
              "tail_entity_id": "T130"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R78",
              "head_entity_id": "T161",
              "tail_entity_id": "T143"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R79",
              "head_entity_id": "T144",
              "tail_entity_id": "T143"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R80",
              "head_entity_id": "T145",
              "tail_entity_id": "T143"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R81",
              "head_entity_id": "T146",
              "tail_entity_id": "T143"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R82",
              "head_entity_id": "T147",
              "tail_entity_id": "T143"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R83",
              "head_entity_id": "T151",
              "tail_entity_id": "T150"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R84",
              "head_entity_id": "T153",
              "tail_entity_id": "T150"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R85",
              "head_entity_id": "T154",
              "tail_entity_id": "T150"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R86",
              "head_entity_id": "T155",
              "tail_entity_id": "T150"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R87",
              "head_entity_id": "T156",
              "tail_entity_id": "T150"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R88",
              "head_entity_id": "T152",
              "tail_entity_id": "T150"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R89",
              "head_entity_id": "T158",
              "tail_entity_id": "T157"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R90",
              "head_entity_id": "T160",
              "tail_entity_id": "T157"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R91",
              "head_entity_id": "T159",
              "tail_entity_id": "T157"
            }
          ],
          "sentence_en": "3.3 Diabetic neuropathy Diabetic neuropathy can mainly affect peripheral nerves, autonomic nerves, cranial nerves, and the brain and spinal cord may also be affected. The early manifestations are demyelination of nerve fibers, axonal degeneration, and Schwann cell proliferation. As the disease progresses, it manifests as axonal degeneration and disappearance of myelin fibers. The most common symptoms of peripheral neuropathy are sensory abnormalities such as numbness and pain, or loss of sensation. When the autonomic nerves are affected, it may manifest as cardiovascular, gastrointestinal, urogenital and sweating disorders or disorders. The most common cranial neuropathy is damage to the oculomotor nerve, followed by the abducens nerve, trochlear nerve, facial nerve and trigeminal nerve. It is often unilaterally affected, and bilateral involvement is rare. Spinal cord lesions are mainly caused by damage to the posterior cord, which is mainly degenerative changes."
        }
      ],
      "paragraph_en": "3.3 Diabetic neuropathy Diabetic neuropathy can mainly affect peripheral nerves, autonomic nerves, cranial nerves, and the brain and spinal cord may also be affected. The early manifestations are demyelination of nerve fibers, axonal degeneration, and Schwann cell proliferation. As the disease progresses, it manifests as axonal degeneration and disappearance of myelin fibers. The most common symptoms of peripheral neuropathy are sensory abnormalities such as numbness and pain, or loss of sensation. When the autonomic nerves are affected, it may manifest as cardiovascular, gastrointestinal, urogenital and sweating disorders or imbalances. The most common cranial neuropathy is damage to the oculomotor nerve, followed by the abducens nerve, trochlear nerve, facial nerve and trigeminal nerve. It is often unilaterally affected, and bilateral involvement is rare. Spinal cord lesions are mainly caused by damage to the posterior cord, which is mainly degenerative changes."
    },
    {
      "paragraph_id": "11",
      "paragraph": "3.4 糖尿病足糖尿病患者因周围神经病变与外周血管疾病合并过高的机械压力，可引起足部过高的机械压力，从而导致足部软组织及骨关节系统的破坏与畸形形成。如果合并不同程度的感染，可从轻度的表皮的浅表感染到严重的坏疽等。如不及时治疗，甚至导致截肢。糖尿病足是目前非创伤性截肢的主要原因。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3.4 糖尿病足糖尿病患者因周围神经病变与外周血管疾病合并过高的机械压力，可引起足部过高的机械压力，从而导致足部软组织及骨关节系统的破坏与畸形形成。",
          "start_idx": 0,
          "end_idx": 74,
          "entities": [
            {
              "entity_id": "T162",
              "entity": "糖尿病足",
              "entity_type": "Disease",
              "start_idx": 4,
              "end_idx": 8,
              "entity_en": "Diabetic foot"
            },
            {
              "entity_id": "T163",
              "entity": "足",
              "entity_type": "Anatomy",
              "start_idx": 7,
              "end_idx": 8,
              "entity_en": "foot"
            },
            {
              "entity_id": "T164",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 8,
              "end_idx": 11,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T170",
              "entity": "周围神经病变",
              "entity_type": "Disease",
              "start_idx": 14,
              "end_idx": 20,
              "entity_en": "Peripheral neuropathy"
            },
            {
              "entity_id": "T171",
              "entity": "外周血管疾病",
              "entity_type": "Disease",
              "start_idx": 21,
              "end_idx": 27,
              "entity_en": "Peripheral vascular disease"
            },
            {
              "entity_id": "T172",
              "entity": "足部",
              "entity_type": "Anatomy",
              "start_idx": 40,
              "end_idx": 42,
              "entity_en": "Foot"
            },
            {
              "entity_id": "T173",
              "entity": "足部软组织",
              "entity_type": "Anatomy",
              "start_idx": 54,
              "end_idx": 59,
              "entity_en": "Foot soft tissue"
            },
            {
              "entity_id": "T174",
              "entity": "骨关节",
              "entity_type": "Anatomy",
              "start_idx": 60,
              "end_idx": 63,
              "entity_en": "Bone and joint"
            },
            {
              "entity_id": "T175",
              "entity": "周围神经",
              "entity_type": "Anatomy",
              "start_idx": 14,
              "end_idx": 18,
              "entity_en": "Peripheral nerves"
            },
            {
              "entity_id": "T176",
              "entity": "外周血管",
              "entity_type": "Anatomy",
              "start_idx": 21,
              "end_idx": 25,
              "entity_en": "Peripheral blood vessels"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R92",
              "head_entity_id": "T163",
              "tail_entity_id": "T162"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R93",
              "head_entity_id": "T173",
              "tail_entity_id": "T162"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R94",
              "head_entity_id": "T174",
              "tail_entity_id": "T162"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R95",
              "head_entity_id": "T172",
              "tail_entity_id": "T162"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R97",
              "head_entity_id": "T175",
              "tail_entity_id": "T170"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R98",
              "head_entity_id": "T176",
              "tail_entity_id": "T171"
            }
          ],
          "sentence_en": "3.4 Diabetic foot Due to peripheral neuropathy and peripheral vascular disease combined with excessive mechanical pressure in diabetic patients, excessive mechanical pressure may be caused in the feet, leading to damage and deformity of the soft tissue and bone and joint system of the feet."
        },
        {
          "sentence_id": "1",
          "sentence": "如果合并不同程度的感染，可从轻度的表皮的浅表感染到严重的坏疽等。",
          "start_idx": 74,
          "end_idx": 106,
          "entities": [
            {
              "entity_id": "T165",
              "entity": "坏疽",
              "entity_type": "Disease",
              "start_idx": 28,
              "end_idx": 30,
              "entity_en": "gangrene"
            }
          ],
          "relations": [],
          "sentence_en": "If combined with different degrees of infection, it can range from mild superficial infection of the epidermis to severe gangrene."
        },
        {
          "sentence_id": "2",
          "sentence": "如不及时治疗，甚至导致截肢。",
          "start_idx": 106,
          "end_idx": 120,
          "entities": [
            {
              "entity_id": "T166",
              "entity": "截肢",
              "entity_type": "Operation",
              "start_idx": 11,
              "end_idx": 13,
              "entity_en": "Amputation"
            }
          ],
          "relations": [],
          "sentence_en": "If not treated promptly, it may even lead to amputation."
        },
        {
          "sentence_id": "3",
          "sentence": "糖尿病足是目前非创伤性截肢的主要原因。",
          "start_idx": 120,
          "end_idx": 139,
          "entities": [
            {
              "entity_id": "T167",
              "entity": "非创伤性截肢",
              "entity_type": "Operation",
              "start_idx": 7,
              "end_idx": 13,
              "entity_en": "Non-traumatic amputation"
            },
            {
              "entity_id": "T168",
              "entity": "糖尿病足",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 4,
              "entity_en": "Diabetic foot"
            },
            {
              "entity_id": "T169",
              "entity": "足",
              "entity_type": "Anatomy",
              "start_idx": 3,
              "end_idx": 4,
              "entity_en": "foot"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R96",
              "head_entity_id": "T169",
              "tail_entity_id": "T168"
            }
          ],
          "sentence_en": "Diabetic foot is currently the leading cause of non-traumatic amputation."
        }
      ],
      "paragraph_en": "3.4 Diabetic foot Due to peripheral neuropathy and peripheral vascular disease combined with excessive mechanical pressure in diabetic patients, excessive mechanical pressure on the feet can be caused, leading to damage and deformity of the soft tissue and bone and joint system of the feet. If combined with varying degrees of infection, it can range from mild superficial infection of the epidermis to severe gangrene. If not treated in time, it may even lead to amputation. Diabetic foot is currently the main cause of non-traumatic amputation."
    },
    {
      "paragraph_id": "12",
      "paragraph": "3.5 其他糖尿病心肌病变可在代谢紊乱及微血管病变的基础上引发心肌广泛局灶性坏死，出现亚临床的心功能异常，最终进展为心力衰竭、心律失常及心源性休克，重症患者甚至猝死。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3.5 其他糖尿病心肌病变可在代谢紊乱及微血管病变的基础上引发心肌广泛局灶性坏死，出现亚临床的心功能异常，最终进展为心力衰竭、心律失常及心源性休克，重症患者甚至猝死。",
          "start_idx": 0,
          "end_idx": 83,
          "entities": [
            {
              "entity_id": "T177",
              "entity": "糖尿病心肌病变",
              "entity_type": "Disease",
              "start_idx": 6,
              "end_idx": 13,
              "entity_en": "Diabetic cardiomyopathy"
            },
            {
              "entity_id": "T178",
              "entity": "心肌",
              "entity_type": "Anatomy",
              "start_idx": 9,
              "end_idx": 11,
              "entity_en": "Myocardium"
            },
            {
              "entity_id": "T179",
              "entity": "代谢紊乱",
              "entity_type": "Disease",
              "start_idx": 15,
              "end_idx": 19,
              "entity_en": "Metabolic disorders"
            },
            {
              "entity_id": "T180",
              "entity": "微血管病变",
              "entity_type": "Disease",
              "start_idx": 20,
              "end_idx": 25,
              "entity_en": "Microangiopathy"
            },
            {
              "entity_id": "T181",
              "entity": "微血管",
              "entity_type": "Anatomy",
              "start_idx": 20,
              "end_idx": 23,
              "entity_en": "Microvascular"
            },
            {
              "entity_id": "T182",
              "entity": "心肌广泛局灶性坏死",
              "entity_type": "Symptom",
              "start_idx": 31,
              "end_idx": 40,
              "entity_en": "Extensive focal myocardial necrosis"
            },
            {
              "entity_id": "T183",
              "entity": "心功能异常",
              "entity_type": "Symptom",
              "start_idx": 47,
              "end_idx": 52,
              "entity_en": "Abnormal heart function"
            },
            {
              "entity_id": "T184",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 58,
              "end_idx": 62,
              "entity_en": "Heart failure"
            },
            {
              "entity_id": "T185",
              "entity": "心律失常",
              "entity_type": "Disease",
              "start_idx": 63,
              "end_idx": 67,
              "entity_en": "Arrhythmias"
            },
            {
              "entity_id": "T186",
              "entity": "心源性休克",
              "entity_type": "Disease",
              "start_idx": 68,
              "end_idx": 73,
              "entity_en": "Cardiogenic shock"
            },
            {
              "entity_id": "T187",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 58,
              "end_idx": 59,
              "entity_en": "Heart"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R99",
              "head_entity_id": "T178",
              "tail_entity_id": "T177"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R100",
              "head_entity_id": "T182",
              "tail_entity_id": "T177"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R101",
              "head_entity_id": "T183",
              "tail_entity_id": "T177"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R102",
              "head_entity_id": "T181",
              "tail_entity_id": "T180"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R103",
              "head_entity_id": "T187",
              "tail_entity_id": "T184"
            }
          ],
          "sentence_en": "3.5 Other diabetic cardiomyopathy can cause extensive focal myocardial necrosis on the basis of metabolic disorders and microvascular diseases, resulting in subclinical cardiac dysfunction, and eventually progressing to heart failure, arrhythmia and cardiogenic shock. Severe patients may even die suddenly."
        }
      ],
      "paragraph_en": "3.5 Other diabetic cardiomyopathy can cause extensive focal myocardial necrosis on the basis of metabolic disorders and microvascular diseases, resulting in subclinical cardiac dysfunction, and eventually progressing to heart failure, arrhythmia and cardiogenic shock. Severe patients may even die suddenly."
    },
    {
      "paragraph_id": "13",
      "paragraph": "糖尿病皮肤病变的发病机理是以微血管病变为主，晚期糖基化终产物蓄积、炎性反应、生长因子改变等参与的多因素的病变过程。临床可表现为胫前色素斑、类脂质渐进性坏死、糖尿病性水疱病、硬肿病和皮肤感染。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "糖尿病皮肤病变的发病机理是以微血管病变为主，晚期糖基化终产物蓄积、炎性反应、生长因子改变等参与的多因素的病变过程。临床可表现为胫前色素斑、类脂质渐进性坏死、糖尿病性水疱病、硬肿病和皮肤感染。",
          "start_idx": 0,
          "end_idx": 95,
          "entities": [
            {
              "entity_id": "T188",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 3,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T189",
              "entity": "皮肤病变",
              "entity_type": "Disease",
              "start_idx": 3,
              "end_idx": 7,
              "entity_en": "Skin lesions"
            },
            {
              "entity_id": "T190",
              "entity": "皮肤",
              "entity_type": "Anatomy",
              "start_idx": 3,
              "end_idx": 5,
              "entity_en": "skin"
            },
            {
              "entity_id": "T191",
              "entity": "微血管病变",
              "entity_type": "Disease",
              "start_idx": 14,
              "end_idx": 19,
              "entity_en": "Microangiopathy"
            },
            {
              "entity_id": "T192",
              "entity": "微血管",
              "entity_type": "Anatomy",
              "start_idx": 14,
              "end_idx": 17,
              "entity_en": "Microvascular"
            },
            {
              "entity_id": "T193",
              "entity": "胫前色素斑",
              "entity_type": "Symptom",
              "start_idx": 63,
              "end_idx": 68,
              "entity_en": "Pretibial pigmentation"
            },
            {
              "entity_id": "T194",
              "entity": "类脂质渐进性坏死",
              "entity_type": "Symptom",
              "start_idx": 69,
              "end_idx": 77,
              "entity_en": "Necrobiosis lipoidica"
            },
            {
              "entity_id": "T195",
              "entity": "糖尿病性水疱病",
              "entity_type": "Symptom",
              "start_idx": 78,
              "end_idx": 85,
              "entity_en": "Diabetic Bullous Disease"
            },
            {
              "entity_id": "T196",
              "entity": "硬肿病",
              "entity_type": "Symptom",
              "start_idx": 86,
              "end_idx": 89,
              "entity_en": "Scleredema"
            },
            {
              "entity_id": "T197",
              "entity": "皮肤感染",
              "entity_type": "Symptom",
              "start_idx": 90,
              "end_idx": 94,
              "entity_en": "Skin infections"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R104",
              "head_entity_id": "T190",
              "tail_entity_id": "T189"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R105",
              "head_entity_id": "T193",
              "tail_entity_id": "T189"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R106",
              "head_entity_id": "T194",
              "tail_entity_id": "T189"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R107",
              "head_entity_id": "T195",
              "tail_entity_id": "T189"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R108",
              "head_entity_id": "T196",
              "tail_entity_id": "T189"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R109",
              "head_entity_id": "T197",
              "tail_entity_id": "T189"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R110",
              "head_entity_id": "T192",
              "tail_entity_id": "T191"
            }
          ],
          "sentence_en": "The pathogenesis of diabetic skin lesions is mainly microvascular disease, and is a multifactorial disease process involving accumulation of advanced glycation end products, inflammatory response, changes in growth factors, etc. Clinically, it can manifest as pretibial pigmentation, progressive necrosis of lipids, diabetic bullous disease, scleredema, and skin infection."
        }
      ],
      "paragraph_en": "The pathogenesis of diabetic skin lesions is mainly microvascular disease, and is a multifactorial disease process involving accumulation of advanced glycation end products, inflammatory response, changes in growth factors, etc. Clinically, it can manifest as pretibial pigmentation, progressive necrosis of lipids, diabetic bullous disease, scleredema, and skin infection."
    },
    {
      "paragraph_id": "14",
      "paragraph": "4 糖尿病微循环障碍的药物治疗",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "4 糖尿病微循环障碍的药物治疗",
          "start_idx": 0,
          "end_idx": 15,
          "entities": [
            {
              "entity_id": "T198",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 5,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T199",
              "entity": "微循环障碍",
              "entity_type": "Symptom",
              "start_idx": 5,
              "end_idx": 10,
              "entity_en": "Microcirculatory disorders"
            }
          ],
          "relations": [
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R111",
              "head_entity_id": "T199",
              "tail_entity_id": "T198"
            }
          ],
          "sentence_en": "4 Drug treatment of diabetic microcirculatory disorders"
        }
      ],
      "paragraph_en": "4 Drug treatment of diabetic microcirculatory disorders"
    },
    {
      "paragraph_id": "15",
      "paragraph": "4.1 用药原则积极控制血糖、血压、血脂仍是糖尿病治疗的基础。微循环障碍贯穿糖尿病病程的始终，改善糖尿病微循环用药应遵循“早期、个体化、合理联合、重视安全”的原则。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "4.1 用药原则积极控制血糖、血压、血脂仍是糖尿病治疗的基础。微循环障碍贯穿糖尿病病程的始终，改善糖尿病微循环用药应遵循“早期、个体化、合理联合、重视安全”的原则。",
          "start_idx": 0,
          "end_idx": 82,
          "entities": [
            {
              "entity_id": "T200",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 12,
              "end_idx": 14,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T201",
              "entity": "血脂",
              "entity_type": "Test_items",
              "start_idx": 18,
              "end_idx": 20,
              "entity_en": "Blood lipids"
            },
            {
              "entity_id": "T202",
              "entity": "微循环障碍",
              "entity_type": "Symptom",
              "start_idx": 31,
              "end_idx": 36,
              "entity_en": "Microcirculatory disorders"
            },
            {
              "entity_id": "T203",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 38,
              "end_idx": 41,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T204",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 49,
              "end_idx": 52,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T205",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 22,
              "end_idx": 25,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T206",
              "entity": "血压",
              "entity_type": "Test",
              "start_idx": 15,
              "end_idx": 17,
              "entity_en": "blood pressure"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R112",
              "head_entity_id": "T200",
              "tail_entity_id": "T205"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R113",
              "head_entity_id": "T201",
              "tail_entity_id": "T205"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R114",
              "head_entity_id": "T202",
              "tail_entity_id": "T203"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R115",
              "head_entity_id": "T206",
              "tail_entity_id": "T205"
            }
          ],
          "sentence_en": "4.1 Medication principles Actively controlling blood sugar, blood pressure, and blood lipids is still the basis of diabetes treatment. Microcirculatory disorders run through the entire course of diabetes. Medication to improve diabetic microcirculation should follow the principles of \"early, individualized, reasonable combination, and emphasis on safety.\""
        }
      ],
      "paragraph_en": "4.1 Medication principles Actively controlling blood sugar, blood pressure, and blood lipids is still the basis of diabetes treatment. Microcirculatory disorders run through the entire course of diabetes. Medication to improve diabetic microcirculation should follow the principles of \"early, individualized, reasonable combination, and emphasis on safety.\""
    },
    {
      "paragraph_id": "16",
      "paragraph": "4.1.1 早期一旦诊断为糖尿病，需尽早做并发症筛查，早诊断，考虑尽早使用改善微循环的药物。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "4.1.1 早期一旦诊断为糖尿病，需尽早做并发症筛查，早诊断，考虑尽早使用改善微循环的药物。",
          "start_idx": 0,
          "end_idx": 46,
          "entities": [
            {
              "entity_id": "T207",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 13,
              "end_idx": 16,
              "entity_en": "diabetes"
            }
          ],
          "relations": [],
          "sentence_en": "4.1.1 Once diabetes is diagnosed in the early stages, screening for complications should be performed as soon as possible, and early diagnosis and use of drugs to improve microcirculation should be considered as soon as possible."
        }
      ],
      "paragraph_en": "4.1.1 Once diabetes is diagnosed in the early stages, screening for complications should be performed as soon as possible, and early diagnosis and use of drugs to improve microcirculation should be considered as soon as possible."
    },
    {
      "paragraph_id": "17",
      "paragraph": "4.1.2 个体化根据不同患者的临床表现特点和药物的作用机制，针对性选择药物，并给予适当疗程(在医生指导下用药和停药)，兼顾风险与获益的平衡。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "4.1.2 个体化根据不同患者的临床表现特点和药物的作用机制，针对性选择药物，并给予适当疗程(在医生指导下用药和停药)，兼顾风险与获益的平衡。",
          "start_idx": 0,
          "end_idx": 71,
          "entities": [],
          "relations": [],
          "sentence_en": "4.1.2 Individualization: Targeted drug selection should be based on the clinical manifestations of different patients and the mechanism of action of the drug, and an appropriate course of treatment should be given (using and stopping the drug under the guidance of a doctor), taking into account the balance between risks and benefits."
        }
      ],
      "paragraph_en": "4.1.2 Individualization: Targeted drug selection should be based on the clinical manifestations of different patients and the mechanism of action of the drug, and an appropriate course of treatment should be given (using and stopping the drug under the guidance of a doctor), taking into account the balance between risks and benefits."
    },
    {
      "paragraph_id": "18",
      "paragraph": "4.1.3 合理联合一般不建议联合用药；如需联合，应遵循机制互补的原则，避免作用机制相同的药物联合，同时注意药物间的相互作用，尤其需考虑患者肝肾功能、年龄等因素。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "4.1.3 合理联合一般不建议联合用药；如需联合，应遵循机制互补的原则，避免作用机制相同的药物联合，同时注意药物间的相互作用，尤其需考虑患者肝肾功能、年龄等因素。",
          "start_idx": 0,
          "end_idx": 81,
          "entities": [],
          "relations": [],
          "sentence_en": "4.1.3 Reasonable combination Combination of drugs is generally not recommended; if combination is necessary, the principle of complementary mechanisms should be followed to avoid combining drugs with the same mechanism of action. At the same time, attention should be paid to drug interactions, especially considering factors such as the patient's liver and kidney function and age."
        }
      ],
      "paragraph_en": "4.1.3 Reasonable combination Combination of drugs is generally not recommended; if combination is necessary, the principle of complementary mechanisms should be followed to avoid combining drugs with the same mechanism of action. At the same time, attention should be paid to drug interactions, especially considering factors such as the patient's liver and kidney function and age."
    },
    {
      "paragraph_id": "19",
      "paragraph": "4.1.4 重视安全严格掌握药物的适应证与禁忌证，注意药物的不良反应。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "4.1.4 重视安全严格掌握药物的适应证与禁忌证，注意药物的不良反应。",
          "start_idx": 0,
          "end_idx": 35,
          "entities": [],
          "relations": [],
          "sentence_en": "4.1.4 Pay attention to safety, strictly follow the indications and contraindications of drugs, and pay attention to adverse reactions of drugs."
        }
      ],
      "paragraph_en": "4.1.4 Pay attention to safety, strictly follow the indications and contraindications of drugs, and pay attention to adverse reactions of drugs."
    },
    {
      "paragraph_id": "20",
      "paragraph": "4.2. 改善糖尿病微循环障碍的药物改善糖尿病微循环障碍的药物主要包括血管扩张药物、影响血液流变学的药物、保护血管内皮的药物以及部分中药制剂等(改善微循环障碍药物的临床推荐意见见表1；常用改善糖尿病微循环障碍药物的简要说明见表2和药品说明书)。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "4.2. 改善糖尿病微循环障碍的药物改善糖尿病微循环障碍的药物主要包括血管扩张药物、影响血液流变学的药物、保护血管内皮的药物以及部分中药制剂等(改善微循环障碍药物的临床推荐意见见表1；常用改善糖尿病微循环障碍药物的简要说明见表2和药品说明书)。",
          "start_idx": 0,
          "end_idx": 122,
          "entities": [
            {
              "entity_id": "T208",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 7,
              "end_idx": 10,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T209",
              "entity": "微循环障碍",
              "entity_type": "Symptom",
              "start_idx": 10,
              "end_idx": 15,
              "entity_en": "Microcirculatory disorders"
            },
            {
              "entity_id": "T210",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 20,
              "end_idx": 23,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T211",
              "entity": "微循环障碍",
              "entity_type": "Symptom",
              "start_idx": 23,
              "end_idx": 28,
              "entity_en": "Microcirculatory disorders"
            },
            {
              "entity_id": "T212",
              "entity": "微循环障碍",
              "entity_type": "Symptom",
              "start_idx": 74,
              "end_idx": 79,
              "entity_en": "Microcirculatory disorders"
            },
            {
              "entity_id": "T213",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 96,
              "end_idx": 99,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T214",
              "entity": "微循环障碍",
              "entity_type": "Symptom",
              "start_idx": 99,
              "end_idx": 104,
              "entity_en": "Microcirculatory disorders"
            }
          ],
          "relations": [
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R116",
              "head_entity_id": "T209",
              "tail_entity_id": "T208"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R117",
              "head_entity_id": "T211",
              "tail_entity_id": "T210"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R118",
              "head_entity_id": "T214",
              "tail_entity_id": "T213"
            }
          ],
          "sentence_en": "4.2. Drugs for improving diabetic microcirculation disorders Drugs for improving diabetic microcirculation disorders mainly include vasodilators, drugs that affect blood rheology, drugs that protect vascular endothelium, and some Chinese herbal preparations (clinical recommendations for drugs for improving microcirculation disorders are shown in Table 1; a brief description of commonly used drugs for improving diabetic microcirculation disorders is shown in Table 2 and the drug instructions)."
        }
      ],
      "paragraph_en": "4.2. Drugs for improving diabetic microcirculation disorders Drugs for improving diabetic microcirculation disorders mainly include vasodilators, drugs that affect blood rheology, drugs that protect vascular endothelium, and some Chinese herbal preparations (clinical recommendations for drugs for improving microcirculation disorders are shown in Table 1; a brief description of commonly used drugs for improving diabetic microcirculation disorders is shown in Table 2 and the drug instructions)."
    },
    {
      "paragraph_id": "21",
      "paragraph": "4.2.1 血管扩张药物",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "4.2.1 血管扩张药物",
          "start_idx": 0,
          "end_idx": 12,
          "entities": [],
          "relations": [],
          "sentence_en": "4.2.1 Vasodilators"
        }
      ],
      "paragraph_en": "4.2.1 Vasodilators"
    },
    {
      "paragraph_id": "22",
      "paragraph": "(1)胰激肽原酶(pancreatic kzllidinogenase，PK)：PK可增加毛细血管血流量；能激活纤溶酶，降低血液黏度，改善血流变；促使肾髓质分泌前列腺素E2，改善组织灌注。临床用于治疗各种微循环障碍性疾病，如糖尿病引起的肾病、周围神经病变、视网膜病变。国外研究提示，PK可以抑制血管增生，有利于控制糖尿病患者视网膜病变。PK在国内具有多年的临床使用经验，但尚需长期大样本及高质量的随机对照研究对其疗效和安全性验证。翟所迪等进行的系统性评价结果提示，PK对糖尿病视网膜病变和糖尿病肾病有一定的疗效。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(1)胰激肽原酶(pancreatic kzllidinogenase，PK)：PK可增加毛细血管血流量；能激活纤溶酶，降低血液黏度，改善血流变；促使肾髓质分泌前列腺素E2，改善组织灌注。临床用于治疗各种微循环障碍性疾病，如糖尿病引起的肾病、周围神经病变、视网膜病变。",
          "start_idx": 0,
          "end_idx": 134,
          "entities": [
            {
              "entity_id": "T215",
              "entity": "胰激肽原酶(pancreatic kzllidinogenase，PK)",
              "entity_type": "Drug",
              "start_idx": 3,
              "end_idx": 39,
              "entity_en": "Pancreatic kallikreinase (PK)"
            },
            {
              "entity_id": "T216",
              "entity": "PK",
              "entity_type": "Drug",
              "start_idx": 40,
              "end_idx": 42,
              "entity_en": "PK"
            },
            {
              "entity_id": "T217",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 112,
              "end_idx": 115,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T218",
              "entity": "肾病",
              "entity_type": "Disease",
              "start_idx": 118,
              "end_idx": 120,
              "entity_en": "Kidney disease"
            },
            {
              "entity_id": "T219",
              "entity": "周围神经病变",
              "entity_type": "Disease",
              "start_idx": 121,
              "end_idx": 127,
              "entity_en": "Peripheral neuropathy"
            },
            {
              "entity_id": "T220",
              "entity": "视网膜病变",
              "entity_type": "Disease",
              "start_idx": 128,
              "end_idx": 133,
              "entity_en": "Retinopathy"
            },
            {
              "entity_id": "T221",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 118,
              "end_idx": 119,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T222",
              "entity": "周围神经",
              "entity_type": "Anatomy",
              "start_idx": 121,
              "end_idx": 125,
              "entity_en": "Peripheral nerves"
            },
            {
              "entity_id": "T223",
              "entity": "视网膜",
              "entity_type": "Anatomy",
              "start_idx": 128,
              "end_idx": 131,
              "entity_en": "Retina"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R119",
              "head_entity_id": "T221",
              "tail_entity_id": "T218"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R120",
              "head_entity_id": "T222",
              "tail_entity_id": "T219"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R121",
              "head_entity_id": "T223",
              "tail_entity_id": "T220"
            }
          ],
          "sentence_en": "(1) Pancreatic kallikreinase (PK): PK can increase capillary blood flow; activate plasmin, reduce blood viscosity, improve blood rheology; promote the secretion of prostaglandin E2 in the renal medulla, and improve tissue perfusion. It is clinically used to treat various microcirculatory disorders, such as diabetic nephropathy, peripheral neuropathy, and retinopathy."
        },
        {
          "sentence_id": "1",
          "sentence": "国外研究提示，PK可以抑制血管增生，有利于控制糖尿病患者视网膜病变。",
          "start_idx": 134,
          "end_idx": 168,
          "entities": [
            {
              "entity_id": "T224",
              "entity": "视网膜病变",
              "entity_type": "Disease",
              "start_idx": 28,
              "end_idx": 33,
              "entity_en": "Retinopathy"
            },
            {
              "entity_id": "T225",
              "entity": "视网膜",
              "entity_type": "Anatomy",
              "start_idx": 28,
              "end_idx": 31,
              "entity_en": "Retina"
            },
            {
              "entity_id": "T226",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 23,
              "end_idx": 26,
              "entity_en": "diabetes"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R122",
              "head_entity_id": "T225",
              "tail_entity_id": "T224"
            }
          ],
          "sentence_en": "Foreign studies suggest that PK can inhibit angiogenesis and help control retinopathy in diabetic patients."
        },
        {
          "sentence_id": "2",
          "sentence": "PK在国内具有多年的临床使用经验，但尚需长期大样本及高质量的随机对照研究对其疗效和安全性验证。",
          "start_idx": 168,
          "end_idx": 215,
          "entities": [],
          "relations": [],
          "sentence_en": "PK has many years of clinical use experience in China, but long-term, large-sample, and high-quality randomized controlled studies are still needed to verify its efficacy and safety."
        },
        {
          "sentence_id": "3",
          "sentence": "翟所迪等进行的系统性评价结果提示，PK对糖尿病视网膜病变和糖尿病肾病有一定的疗效。",
          "start_idx": 215,
          "end_idx": 256,
          "entities": [
            {
              "entity_id": "T227",
              "entity": "糖尿病视网膜病变",
              "entity_type": "Disease",
              "start_idx": 20,
              "end_idx": 28,
              "entity_en": "Diabetic retinopathy"
            },
            {
              "entity_id": "T228",
              "entity": "视网膜",
              "entity_type": "Anatomy",
              "start_idx": 23,
              "end_idx": 26,
              "entity_en": "Retina"
            },
            {
              "entity_id": "T229",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 29,
              "end_idx": 34,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T230",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 32,
              "end_idx": 33,
              "entity_en": "kidney"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R123",
              "head_entity_id": "T228",
              "tail_entity_id": "T227"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R124",
              "head_entity_id": "T230",
              "tail_entity_id": "T229"
            }
          ],
          "sentence_en": "The results of a systematic evaluation conducted by Zhai Suodi et al. suggest that PK has a certain therapeutic effect on diabetic retinopathy and diabetic nephropathy."
        }
      ],
      "paragraph_en": "(1) Pancreatic kallikreinase (PK): PK can increase capillary blood flow; activate plasmin, reduce blood viscosity, and improve blood rheology; promote the secretion of prostaglandin E2 in the renal medulla and improve tissue perfusion. It is clinically used to treat various microcirculatory disorders, such as diabetic nephropathy, peripheral neuropathy, and retinopathy. Foreign studies have shown that PK can inhibit vascular proliferation and help control retinopathy in diabetic patients. PK has many years of clinical experience in China, but long-term large-sample and high-quality randomized controlled studies are still needed to verify its efficacy and safety. The results of a systematic evaluation conducted by Zhai Suodi et al. showed that PK has a certain effect on diabetic retinopathy and diabetic nephropathy."
    },
    {
      "paragraph_id": "23",
      "paragraph": "(2)前列地尔：即前列腺素E1(prostaglandin1，PGE1)，增加血管平滑肌细胞内环磷酸腺苷(cyclic adenosine monophosphate，cAMP)含量，舒张血管平滑肌，发挥强大的扩血管作用，尤其对阻塞部位的血管作用显著。通过降低血液黏度，改善红细胞变形能力从而改善微循环。临床上用于治疗慢性动脉闭塞症引起的四肢溃疡及微小血管循环障碍引起的四肢静息疼痛。荟萃分析显示，PGE1可以缓解疼痛，增加无痛行走距离(pain-free walking distance，PFWD)和最大行走距离(maximum walking distance，MWD)且效果持续，促进溃疡愈合，降低截肢率。对于糖尿病神经病变的患者，荟萃分析结果显示，PGE1联合甲钴胺对糖尿病周围神经病变症状和体征改善的总有效率和对平均运动神经传导速度(motor nerve conduction velocity，MNCV)的改善优于单用甲钴胺。对于糖尿病合并肾功能不全的患者，荟萃分析结果显示，PGE1联合常规治疗，可显著降低尿白蛋白排出率(urinary albumin excretion rate，UAER)。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(2)前列地尔：即前列腺素E1(prostaglandin1，PGE1)，增加血管平滑肌细胞内环磷酸腺苷(cyclic adenosine monophosphate，cAMP)含量，舒张血管平滑肌，发挥强大的扩血管作用，尤其对阻塞部位的血管作用显著。通过降低血液黏度，改善红细胞变形能力从而改善微循环。临床上用于治疗慢性动脉闭塞症引起的四肢溃疡及微小血管循环障碍引起的四肢静息疼痛。荟萃分析显示，PGE1可以缓解疼痛，增加无痛行走距离(pain-free walking distance，PFWD)和最大行走距离(maximum walking distance，MWD)且效果持续，促进溃疡愈合，降低截肢率。对于糖尿病神经病变的患者，荟萃分析结果显示，PGE1联合甲钴胺对糖尿病周围神经病变症状和体征改善的总有效率和对平均运动神经传导速度(motor nerve conduction velocity，MNCV)的改善优于单用甲钴胺。对于糖尿病合并肾功能不全的患者，荟萃分析结果显示，PGE1联合常规治疗，可显著降低尿白蛋白排出率(urinary albumin excretion rate，UAER)。",
          "start_idx": 0,
          "end_idx": 507,
          "entities": [
            {
              "entity_id": "T231",
              "entity": "前列地尔",
              "entity_type": "Drug",
              "start_idx": 3,
              "end_idx": 7,
              "entity_en": "Alprostadil"
            },
            {
              "entity_id": "T232",
              "entity": "前列腺素E1(prostaglandin1，PGE1)",
              "entity_type": "Drug",
              "start_idx": 9,
              "end_idx": 36,
              "entity_en": "Prostaglandin E1 (PGE1)"
            },
            {
              "entity_id": "T233",
              "entity": "慢性动脉闭塞症",
              "entity_type": "Disease",
              "start_idx": 159,
              "end_idx": 166,
              "entity_en": "Chronic arterial occlusive disease"
            },
            {
              "entity_id": "T234",
              "entity": "四肢溃疡",
              "entity_type": "Symptom",
              "start_idx": 169,
              "end_idx": 173,
              "entity_en": "Limb ulcers"
            },
            {
              "entity_id": "T235",
              "entity": "微小血管循环障碍",
              "entity_type": "Symptom",
              "start_idx": 174,
              "end_idx": 182,
              "entity_en": "Microvascular circulatory disorder"
            },
            {
              "entity_id": "T236",
              "entity": "四肢静息疼痛",
              "entity_type": "Symptom",
              "start_idx": 185,
              "end_idx": 191,
              "entity_en": "Resting pain in limbs"
            },
            {
              "entity_id": "T237",
              "entity": "糖尿病神经病变",
              "entity_type": "Disease",
              "start_idx": 309,
              "end_idx": 316,
              "entity_en": "Diabetic neuropathy"
            },
            {
              "entity_id": "T238",
              "entity": "神经",
              "entity_type": "Anatomy",
              "start_idx": 312,
              "end_idx": 314,
              "entity_en": "nerve"
            },
            {
              "entity_id": "T239",
              "entity": "PGE1",
              "entity_type": "Drug",
              "start_idx": 329,
              "end_idx": 333,
              "entity_en": "PGE1"
            },
            {
              "entity_id": "T240",
              "entity": "甲钴胺",
              "entity_type": "Drug",
              "start_idx": 335,
              "end_idx": 338,
              "entity_en": "Methylcobalamin"
            },
            {
              "entity_id": "T241",
              "entity": "糖尿病周围神经病变",
              "entity_type": "Disease",
              "start_idx": 339,
              "end_idx": 348,
              "entity_en": "Diabetic peripheral neuropathy"
            },
            {
              "entity_id": "T242",
              "entity": "神经",
              "entity_type": "Anatomy",
              "start_idx": 344,
              "end_idx": 346,
              "entity_en": "nerve"
            },
            {
              "entity_id": "T243",
              "entity": "甲钴胺",
              "entity_type": "Drug",
              "start_idx": 417,
              "end_idx": 420,
              "entity_en": "Methylcobalamin"
            },
            {
              "entity_id": "T244",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 423,
              "end_idx": 426,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T245",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 428,
              "end_idx": 433,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T246",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 428,
              "end_idx": 429,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T247",
              "entity": "PGE1",
              "entity_type": "Drug",
              "start_idx": 446,
              "end_idx": 450,
              "entity_en": "PGE1"
            },
            {
              "entity_id": "T248",
              "entity": "尿白蛋白排出率(urinary albumin excretion rate，UAER)",
              "entity_type": "Test_items",
              "start_idx": 462,
              "end_idx": 506,
              "entity_en": "Urinary albumin excretion rate (UAER)"
            }
          ],
          "relations": [
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R125",
              "head_entity_id": "T234",
              "tail_entity_id": "T233"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R126",
              "head_entity_id": "T235",
              "tail_entity_id": "T233"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R127",
              "head_entity_id": "T236",
              "tail_entity_id": "T233"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R128",
              "head_entity_id": "T238",
              "tail_entity_id": "T237"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R129",
              "head_entity_id": "T239",
              "tail_entity_id": "T241"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R130",
              "head_entity_id": "T240",
              "tail_entity_id": "T241"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R131",
              "head_entity_id": "T242",
              "tail_entity_id": "T241"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R132",
              "head_entity_id": "T247",
              "tail_entity_id": "T244"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R133",
              "head_entity_id": "T248",
              "tail_entity_id": "T244"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R134",
              "head_entity_id": "T246",
              "tail_entity_id": "T245"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R135",
              "head_entity_id": "T247",
              "tail_entity_id": "T245"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R136",
              "head_entity_id": "T248",
              "tail_entity_id": "T245"
            }
          ],
          "sentence_en": "(2) Alprostadil: Prostaglandin E1 (PGE1) increases the content of cyclic adenosine monophosphate (cAMP) in vascular smooth muscle cells, relaxes vascular smooth muscle, and exerts a powerful vasodilation effect, especially on blood vessels at blocked sites. It improves microcirculation by reducing blood viscosity and improving red blood cell deformability. It is clinically used to treat limb ulcers caused by chronic arterial occlusive disease and resting pain in the limbs caused by microvascular circulatory disorders. Meta-analysis shows that PGE1 can relieve pain, increase pain-free walking distance (PFWD) and maximum walking distance (MWD) with sustained effects, promote ulcer healing, and reduce amputation rates. For patients with diabetic neuropathy, meta-analysis results show that the total effective rate of PGE1 combined with methylcobalamin in improving the symptoms and signs of diabetic peripheral neuropathy and the improvement of mean motor nerve conduction velocity (MNCV) is better than that of methylcobalamin alone. For patients with diabetes and renal insufficiency, meta-analysis results showed that PGE1 combined with conventional treatment can significantly reduce the urinary albumin excretion rate (UAER)."
        }
      ],
      "paragraph_en": "(2) Alprostadil: Prostaglandin E1 (PGE1) increases the content of cyclic adenosine monophosphate (cAMP) in vascular smooth muscle cells, relaxes vascular smooth muscle, and exerts a powerful vasodilation effect, especially on blood vessels at blocked sites. It improves microcirculation by reducing blood viscosity and improving red blood cell deformability. It is clinically used to treat limb ulcers caused by chronic arterial occlusive disease and resting pain in the limbs caused by microvascular circulatory disorders. Meta-analysis shows that PGE1 can relieve pain, increase pain-free walking distance (PFWD) and maximum walking distance (MWD) with sustained effects, promote ulcer healing, and reduce amputation rates. For patients with diabetic neuropathy, meta-analysis results show that the total effective rate of PGE1 combined with methylcobalamin in improving the symptoms and signs of diabetic peripheral neuropathy and the improvement of mean motor nerve conduction velocity (MNCV) is better than that of methylcobalamin alone. For patients with diabetes and renal insufficiency, meta-analysis results showed that PGE1 combined with conventional treatment can significantly reduce the urinary albumin excretion rate (UAER)."
    },
    {
      "paragraph_id": "24",
      "paragraph": "(3)贝前列素钠：通过作用于血小板和血管平滑肌的前列环素受体，发挥抗血小板和扩张血管作用，从而改善微循环。临床上用于改善慢性动脉闭塞性疾病引起的溃疡、间歇性跛行、疼痛和冷感等症状。一项多中心、随机、双盲、对照研究显示，贝前列素钠治疗3~6个月可以显著改善间歇性跛行患者的PFWD和MWD。另一项随机双盲对照研究证实，慢性糖尿病足溃疡患者接受6周贝前列素钠治疗后，中位创面愈合率较安慰剂组显著提高。中国一项随机对照研究结果显示，前列地尔和前列地尔-贝前列素钠序贯治疗糖尿病肾病患者，均能显著降低尿微量白蛋白及尿总蛋白水平。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(3)贝前列素钠：通过作用于血小板和血管平滑肌的前列环素受体，发挥抗血小板和扩张血管作用，从而改善微循环。临床上用于改善慢性动脉闭塞性疾病引起的溃疡、间歇性跛行、疼痛和冷感等症状。一项多中心、随机、双盲、对照研究显示，贝前列素钠治疗3~6个月可以显著改善间歇性跛行患者的PFWD和MWD。另一项随机双盲对照研究证实，慢性糖尿病足溃疡患者接受6周贝前列素钠治疗后，中位创面愈合率较安慰剂组显著提高。中国一项随机对照研究结果显示，前列地尔和前列地尔-贝前列素钠序贯治疗糖尿病肾病患者，均能显著降低尿微量白蛋白及尿总蛋白水平。",
          "start_idx": 0,
          "end_idx": 260,
          "entities": [
            {
              "entity_id": "T249",
              "entity": "贝前列素钠",
              "entity_type": "Drug",
              "start_idx": 3,
              "end_idx": 8,
              "entity_en": "Beraprost Sodium"
            },
            {
              "entity_id": "T250",
              "entity": "慢性动脉闭塞性疾病",
              "entity_type": "Disease",
              "start_idx": 60,
              "end_idx": 69,
              "entity_en": "Chronic arterial occlusive disease"
            },
            {
              "entity_id": "T251",
              "entity": "溃疡",
              "entity_type": "Symptom",
              "start_idx": 72,
              "end_idx": 74,
              "entity_en": "ulcer"
            },
            {
              "entity_id": "T252",
              "entity": "间歇性跛行",
              "entity_type": "Symptom",
              "start_idx": 75,
              "end_idx": 80,
              "entity_en": "Intermittent claudication"
            },
            {
              "entity_id": "T253",
              "entity": "疼痛",
              "entity_type": "Symptom",
              "start_idx": 81,
              "end_idx": 83,
              "entity_en": "pain"
            },
            {
              "entity_id": "T254",
              "entity": "冷感",
              "entity_type": "Symptom",
              "start_idx": 84,
              "end_idx": 86,
              "entity_en": "Cold"
            },
            {
              "entity_id": "T255",
              "entity": "贝前列素钠",
              "entity_type": "Drug",
              "start_idx": 109,
              "end_idx": 114,
              "entity_en": "Beraprost Sodium"
            },
            {
              "entity_id": "T256",
              "entity": "3~6个月",
              "entity_type": "Duration",
              "start_idx": 116,
              "end_idx": 121,
              "entity_en": "3~6 months"
            },
            {
              "entity_id": "T257",
              "entity": "间歇性跛行",
              "entity_type": "Disease",
              "start_idx": 127,
              "end_idx": 132,
              "entity_en": "Intermittent claudication"
            },
            {
              "entity_id": "T258",
              "entity": "慢性糖尿病",
              "entity_type": "Disease",
              "start_idx": 158,
              "end_idx": 163,
              "entity_en": "Chronic diabetes"
            },
            {
              "entity_id": "T259",
              "entity": "足溃疡",
              "entity_type": "Symptom",
              "start_idx": 163,
              "end_idx": 166,
              "entity_en": "Foot ulcer"
            },
            {
              "entity_id": "T260",
              "entity": "6周",
              "entity_type": "Duration",
              "start_idx": 170,
              "end_idx": 172,
              "entity_en": "6 weeks"
            },
            {
              "entity_id": "T261",
              "entity": "贝前列素钠",
              "entity_type": "Drug",
              "start_idx": 172,
              "end_idx": 177,
              "entity_en": "Beraprost Sodium"
            },
            {
              "entity_id": "T262",
              "entity": "前列地尔",
              "entity_type": "Drug",
              "start_idx": 213,
              "end_idx": 217,
              "entity_en": "Alprostadil"
            },
            {
              "entity_id": "T263",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 232,
              "end_idx": 237,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T264",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 235,
              "end_idx": 236,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T265",
              "entity": "微量白蛋白",
              "entity_type": "Test_items",
              "start_idx": 247,
              "end_idx": 252,
              "entity_en": "Microalbumin"
            },
            {
              "entity_id": "T266",
              "entity": "尿总蛋白",
              "entity_type": "Test_items",
              "start_idx": 253,
              "end_idx": 257,
              "entity_en": "Urine total protein"
            },
            {
              "entity_id": "T267",
              "entity": "前列地尔",
              "entity_type": "Drug",
              "start_idx": 218,
              "end_idx": 222,
              "entity_en": "Alprostadil"
            },
            {
              "entity_id": "T268",
              "entity": "贝前列素钠",
              "entity_type": "Drug",
              "start_idx": 223,
              "end_idx": 228,
              "entity_en": "Beraprost Sodium"
            }
          ],
          "relations": [
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R137",
              "head_entity_id": "T251",
              "tail_entity_id": "T250"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R138",
              "head_entity_id": "T252",
              "tail_entity_id": "T250"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R139",
              "head_entity_id": "T253",
              "tail_entity_id": "T250"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R140",
              "head_entity_id": "T254",
              "tail_entity_id": "T250"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R141",
              "head_entity_id": "T255",
              "tail_entity_id": "T257"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R142",
              "head_entity_id": "T256",
              "tail_entity_id": "T255"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R143",
              "head_entity_id": "T259",
              "tail_entity_id": "T258"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R144",
              "head_entity_id": "T261",
              "tail_entity_id": "T258"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R145",
              "head_entity_id": "T260",
              "tail_entity_id": "T261"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R146",
              "head_entity_id": "T262",
              "tail_entity_id": "T263"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R147",
              "head_entity_id": "T264",
              "tail_entity_id": "T263"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R148",
              "head_entity_id": "T265",
              "tail_entity_id": "T263"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R149",
              "head_entity_id": "T266",
              "tail_entity_id": "T263"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R150",
              "head_entity_id": "T267",
              "tail_entity_id": "T263"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R151",
              "head_entity_id": "T268",
              "tail_entity_id": "T263"
            }
          ],
          "sentence_en": "(3) Beraprost sodium: It acts on the prostacyclin receptors of platelets and vascular smooth muscle to exert antiplatelet and vasodilator effects, thereby improving microcirculation. It is clinically used to improve symptoms such as ulcers, intermittent claudication, pain and cold sensation caused by chronic arterial occlusive disease. A multicenter, randomized, double-blind, controlled study showed that 3-6 months of treatment with beraprost sodium can significantly improve PFWD and MWD in patients with intermittent claudication. Another randomized, double-blind controlled study confirmed that the median wound healing rate of patients with chronic diabetic foot ulcers after 6 weeks of beraprost sodium treatment was significantly higher than that of the placebo group. The results of a randomized controlled study in China showed that alprostadil and alprostadil-beraprost sodium sequential treatment in patients with diabetic nephropathy can significantly reduce the levels of urinary microalbumin and total protein in urine."
        }
      ],
      "paragraph_en": "(3) Beraprost sodium: It acts on the prostacyclin receptors of platelets and vascular smooth muscle to exert antiplatelet and vasodilator effects, thereby improving microcirculation. It is clinically used to improve symptoms such as ulcers, intermittent claudication, pain and cold sensation caused by chronic arterial occlusive disease. A multicenter, randomized, double-blind, controlled study showed that 3-6 months of treatment with beraprost sodium can significantly improve PFWD and MWD in patients with intermittent claudication. Another randomized, double-blind controlled study confirmed that the median wound healing rate of patients with chronic diabetic foot ulcers after 6 weeks of beraprost sodium treatment was significantly higher than that of the placebo group. The results of a randomized controlled study in China showed that alprostadil and alprostadil-beraprost sodium sequential treatment in patients with diabetic nephropathy can significantly reduce the levels of urinary microalbumin and total protein in urine."
    },
    {
      "paragraph_id": "25",
      "paragraph": "其他血管扩张药，如尼莫地平、桂哌齐特等钙离子通道阻滞剂，也可改善微血管痉挛和纠正缺血。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "其他血管扩张药，如尼莫地平、桂哌齐特等钙离子通道阻滞剂，也可改善微血管痉挛和纠正缺血。",
          "start_idx": 0,
          "end_idx": 43,
          "entities": [
            {
              "entity_id": "T269",
              "entity": "尼莫地平",
              "entity_type": "Drug",
              "start_idx": 9,
              "end_idx": 13,
              "entity_en": "Nimodipine"
            },
            {
              "entity_id": "T270",
              "entity": "桂哌齐特",
              "entity_type": "Drug",
              "start_idx": 14,
              "end_idx": 18,
              "entity_en": "Cimepazide"
            },
            {
              "entity_id": "T271",
              "entity": "钙离子通道阻滞剂",
              "entity_type": "Drug",
              "start_idx": 19,
              "end_idx": 27,
              "entity_en": "Calcium channel blockers"
            }
          ],
          "relations": [],
          "sentence_en": "Other vasodilators, such as calcium channel blockers such as nimodipine and cinepazide, can also improve microvascular spasm and correct ischemia."
        }
      ],
      "paragraph_en": "Other vasodilators, such as calcium channel blockers such as nimodipine and cinepazide, can also improve microvascular spasm and correct ischemia."
    },
    {
      "paragraph_id": "26",
      "paragraph": "4.2.2 影响血液流变学的药物",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "4.2.2 影响血液流变学的药物",
          "start_idx": 0,
          "end_idx": 16,
          "entities": [],
          "relations": [],
          "sentence_en": "4.2.2 Drugs that affect blood rheology"
        }
      ],
      "paragraph_en": "4.2.2 Drugs that affect blood rheology"
    },
    {
      "paragraph_id": "27",
      "paragraph": "(1)不同类型的抗血小板药：抗血小板的药物甚多，其主要作用是抑制血小板功能。氯吡格雷和噻氯匹定等药物是一类抑制二磷酸腺苷介导的血小板活化的新型抗血小板药。盐酸沙格雷酯是5-羟色胺2(5-hydroxytryptamine 2，5-HT2)受体拮抗剂，对血小板以及对血管平滑肌的5-HT2受体具有特异性拮抗作用，从而抑制5-HT2受体介导的血小板凝聚、抑制血管收缩和平滑肌细胞增殖，改善红细胞的变形能力，改善侧支循环，升高慢性动脉闭塞症患者的经皮氧分压以皮肤表面温度，改善微循环障碍。盐酸沙格雷酯可改善包括糖尿病周围血管病变引起的疼痛、冷感、溃疡等多种症状。一项随机对照研究显示，盐酸沙格雷酯治疗能有效增加糖尿病下肢血管病变患者MWD和PFWD，部分改善足背动脉和胫后动脉的流速、阻力指数和踝肱指数(ankle brachial index，ABI)。一项纳入了9个随机对照研究的荟萃分析结果显示，盐酸沙格雷酯治疗下肢血管病变，能减小患者溃疡面积，增加ABI、足背动脉血流量和PFWD。另一项研究显示，盐酸沙雷酯可降低早期糖尿病肾病患者蛋白尿，延缓肾病发展。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(1)不同类型的抗血小板药：抗血小板的药物甚多，其主要作用是抑制血小板功能。氯吡格雷和噻氯匹定等药物是一类抑制二磷酸腺苷介导的血小板活化的新型抗血小板药。盐酸沙格雷酯是5-羟色胺2(5-hydroxytryptamine 2，5-HT2)受体拮抗剂，对血小板以及对血管平滑肌的5-HT2受体具有特异性拮抗作用，从而抑制5-HT2受体介导的血小板凝聚、抑制血管收缩和平滑肌细胞增殖，改善红细胞的变形能力，改善侧支循环，升高慢性动脉闭塞症患者的经皮氧分压以皮肤表面温度，改善微循环障碍。盐酸沙格雷酯可改善包括糖尿病周围血管病变引起的疼痛、冷感、溃疡等多种症状。一项随机对照研究显示，盐酸沙格雷酯治疗能有效增加糖尿病下肢血管病变患者MWD和PFWD，部分改善足背动脉和胫后动脉的流速、阻力指数和踝肱指数(ankle brachial index，ABI)。一项纳入了9个随机对照研究的荟萃分析结果显示，盐酸沙格雷酯治疗下肢血管病变，能减小患者溃疡面积，增加ABI、足背动脉血流量和PFWD。另一项研究显示，盐酸沙雷酯可降低早期糖尿病肾病患者蛋白尿，延缓肾病发展。",
          "start_idx": 0,
          "end_idx": 478,
          "entities": [
            {
              "entity_id": "T272",
              "entity": "氯吡格雷",
              "entity_type": "Drug",
              "start_idx": 38,
              "end_idx": 42,
              "entity_en": "Clopidogrel"
            },
            {
              "entity_id": "T273",
              "entity": "噻氯匹定",
              "entity_type": "Drug",
              "start_idx": 43,
              "end_idx": 47,
              "entity_en": "Ticlopidine"
            },
            {
              "entity_id": "T274",
              "entity": "盐酸沙格雷酯",
              "entity_type": "Drug",
              "start_idx": 77,
              "end_idx": 83,
              "entity_en": "Sarpogrelate hydrochloride"
            },
            {
              "entity_id": "T275",
              "entity": "5-羟色胺2(5-hydroxytryptamine 2，5-HT2)受体拮抗剂",
              "entity_type": "Drug",
              "start_idx": 84,
              "end_idx": 124,
              "entity_en": "5-hydroxytryptamine 2 (5-HT2) receptor antagonists"
            },
            {
              "entity_id": "T276",
              "entity": "慢性动脉闭塞症",
              "entity_type": "Disease",
              "start_idx": 210,
              "end_idx": 217,
              "entity_en": "Chronic arterial occlusive disease"
            },
            {
              "entity_id": "T277",
              "entity": "微循环障碍",
              "entity_type": "Symptom",
              "start_idx": 235,
              "end_idx": 240,
              "entity_en": "Microcirculatory disorders"
            },
            {
              "entity_id": "T278",
              "entity": "动脉",
              "entity_type": "Anatomy",
              "start_idx": 212,
              "end_idx": 214,
              "entity_en": "artery"
            },
            {
              "entity_id": "T279",
              "entity": "盐酸沙格雷酯",
              "entity_type": "Drug",
              "start_idx": 241,
              "end_idx": 247,
              "entity_en": "Sarpogrelate hydrochloride"
            },
            {
              "entity_id": "T280",
              "entity": "糖尿病周围血管病",
              "entity_type": "Disease",
              "start_idx": 252,
              "end_idx": 260,
              "entity_en": "Diabetic peripheral vascular disease"
            },
            {
              "entity_id": "T281",
              "entity": "周围血管",
              "entity_type": "Anatomy",
              "start_idx": 255,
              "end_idx": 259,
              "entity_en": "Peripheral blood vessels"
            },
            {
              "entity_id": "T282",
              "entity": "疼痛",
              "entity_type": "Symptom",
              "start_idx": 264,
              "end_idx": 266,
              "entity_en": "pain"
            },
            {
              "entity_id": "T283",
              "entity": "冷感",
              "entity_type": "Symptom",
              "start_idx": 267,
              "end_idx": 269,
              "entity_en": "Cold"
            },
            {
              "entity_id": "T284",
              "entity": "溃疡",
              "entity_type": "Symptom",
              "start_idx": 270,
              "end_idx": 272,
              "entity_en": "ulcer"
            },
            {
              "entity_id": "T285",
              "entity": "盐酸沙格雷酯",
              "entity_type": "Drug",
              "start_idx": 289,
              "end_idx": 295,
              "entity_en": "Sarpogrelate hydrochloride"
            },
            {
              "entity_id": "T286",
              "entity": "糖尿病下肢血管病变",
              "entity_type": "Disease",
              "start_idx": 302,
              "end_idx": 311,
              "entity_en": "Diabetic lower extremity vascular disease"
            },
            {
              "entity_id": "T287",
              "entity": "下肢血管",
              "entity_type": "Anatomy",
              "start_idx": 305,
              "end_idx": 309,
              "entity_en": "Lower limb blood vessels"
            },
            {
              "entity_id": "T288",
              "entity": "盐酸沙格雷酯",
              "entity_type": "Drug",
              "start_idx": 398,
              "end_idx": 404,
              "entity_en": "Sarpogrelate hydrochloride"
            },
            {
              "entity_id": "T289",
              "entity": "下肢血管病变",
              "entity_type": "Disease",
              "start_idx": 406,
              "end_idx": 412,
              "entity_en": "Lower extremity vascular disease"
            },
            {
              "entity_id": "T290",
              "entity": "下肢血管",
              "entity_type": "Anatomy",
              "start_idx": 406,
              "end_idx": 410,
              "entity_en": "Lower limb blood vessels"
            },
            {
              "entity_id": "T291",
              "entity": "盐酸沙雷酯",
              "entity_type": "Drug",
              "start_idx": 450,
              "end_idx": 455,
              "entity_en": "Seratate hydrochloride"
            },
            {
              "entity_id": "T292",
              "entity": "早期",
              "entity_type": "Class",
              "start_idx": 458,
              "end_idx": 460,
              "entity_en": "Early"
            },
            {
              "entity_id": "T293",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 460,
              "end_idx": 465,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T294",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 463,
              "end_idx": 464,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T295",
              "entity": "蛋白尿",
              "entity_type": "Symptom",
              "start_idx": 467,
              "end_idx": 470,
              "entity_en": "Proteinuria"
            },
            {
              "entity_id": "T296",
              "entity": "肾病",
              "entity_type": "Disease",
              "start_idx": 473,
              "end_idx": 475,
              "entity_en": "Kidney disease"
            },
            {
              "entity_id": "T297",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 473,
              "end_idx": 474,
              "entity_en": "kidney"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R152",
              "head_entity_id": "T274",
              "tail_entity_id": "T276"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R153",
              "head_entity_id": "T275",
              "tail_entity_id": "T276"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R154",
              "head_entity_id": "T278",
              "tail_entity_id": "T276"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R155",
              "head_entity_id": "T279",
              "tail_entity_id": "T280"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R156",
              "head_entity_id": "T281",
              "tail_entity_id": "T280"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R157",
              "head_entity_id": "T282",
              "tail_entity_id": "T280"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R158",
              "head_entity_id": "T283",
              "tail_entity_id": "T280"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R159",
              "head_entity_id": "T284",
              "tail_entity_id": "T280"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R160",
              "head_entity_id": "T285",
              "tail_entity_id": "T286"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R161",
              "head_entity_id": "T287",
              "tail_entity_id": "T286"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R162",
              "head_entity_id": "T288",
              "tail_entity_id": "T289"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R163",
              "head_entity_id": "T290",
              "tail_entity_id": "T289"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R164",
              "head_entity_id": "T291",
              "tail_entity_id": "T293"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R165",
              "head_entity_id": "T292",
              "tail_entity_id": "T293"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R166",
              "head_entity_id": "T294",
              "tail_entity_id": "T293"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R167",
              "head_entity_id": "T295",
              "tail_entity_id": "T293"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R168",
              "head_entity_id": "T297",
              "tail_entity_id": "T296"
            }
          ],
          "sentence_en": "(1) Different types of antiplatelet drugs: There are many antiplatelet drugs, and their main function is to inhibit platelet function. Clopidogrel and ticlopidine are new antiplatelet drugs that inhibit adenosine diphosphate-mediated platelet activation. Sarpogrelate hydrochloride is a 5-hydroxytryptamine 2 (5-HT2) receptor antagonist, which has a specific antagonistic effect on platelets and 5-HT2 receptors of vascular smooth muscle, thereby inhibiting 5-HT2 receptor-mediated platelet aggregation, inhibiting vasoconstriction and smooth muscle cell proliferation, improving red blood cell deformability, improving collateral circulation, increasing transcutaneous oxygen partial pressure and skin surface temperature in patients with chronic arterial occlusive disease, and improving microcirculatory disorders. Sarpogrelate hydrochloride can improve a variety of symptoms including pain, cold sensation, ulcers, etc. caused by diabetic peripheral vascular disease. A randomized controlled study showed that sarpogrelate hydrochloride treatment can effectively increase MWD and PFWD in patients with diabetic lower limb vascular disease, and partially improve the flow velocity, resistance index and ankle brachial index (ABI) of the dorsalis pedis artery and posterior tibial artery. A meta-analysis of 9 randomized controlled studies showed that sarpogrelate hydrochloride treatment of lower limb vascular disease can reduce the ulcer area of patients, increase ABI, dorsalis pedis artery blood flow and PFWD. Another study showed that sarpogrelate hydrochloride can reduce proteinuria in patients with early diabetic nephropathy and delay the development of nephropathy."
        }
      ],
      "paragraph_en": "(1) Different types of antiplatelet drugs: There are many antiplatelet drugs, and their main function is to inhibit platelet function. Clopidogrel and ticlopidine are new antiplatelet drugs that inhibit adenosine diphosphate-mediated platelet activation. Sarpogrelate hydrochloride is a 5-hydroxytryptamine 2 (5-HT2) receptor antagonist, which has a specific antagonistic effect on platelets and 5-HT2 receptors of vascular smooth muscle, thereby inhibiting 5-HT2 receptor-mediated platelet aggregation, inhibiting vasoconstriction and smooth muscle cell proliferation, improving red blood cell deformability, improving collateral circulation, increasing transcutaneous oxygen partial pressure and skin surface temperature in patients with chronic arterial occlusive disease, and improving microcirculatory disorders. Sarpogrelate hydrochloride can improve a variety of symptoms including pain, cold sensation, ulcers, etc. caused by diabetic peripheral vascular disease. A randomized controlled study showed that sarpogrelate hydrochloride treatment can effectively increase MWD and PFWD in patients with diabetic lower limb vascular disease, and partially improve the flow velocity, resistance index and ankle brachial index (ABI) of the dorsalis pedis artery and posterior tibial artery. A meta-analysis of 9 randomized controlled studies showed that sarpogrelate hydrochloride treatment of lower limb vascular disease can reduce the ulcer area of patients, increase ABI, dorsalis pedis artery blood flow and PFWD. Another study showed that sarpogrelate hydrochloride can reduce proteinuria in patients with early diabetic nephropathy and delay the development of nephropathy."
    },
    {
      "paragraph_id": "28",
      "paragraph": "其他抗血小板药包括阿司匹林、双嘧达莫(潘生丁)和西洛他唑等。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "其他抗血小板药包括阿司匹林、双嘧达莫(潘生丁)和西洛他唑等。",
          "start_idx": 0,
          "end_idx": 30,
          "entities": [
            {
              "entity_id": "T298",
              "entity": "阿司匹林",
              "entity_type": "Drug",
              "start_idx": 9,
              "end_idx": 13,
              "entity_en": "aspirin"
            },
            {
              "entity_id": "T299",
              "entity": "双嘧达莫(潘生丁)",
              "entity_type": "Drug",
              "start_idx": 14,
              "end_idx": 23,
              "entity_en": "Dipyridamole (Dipyridamole)"
            },
            {
              "entity_id": "T300",
              "entity": "西洛他唑",
              "entity_type": "Drug",
              "start_idx": 24,
              "end_idx": 28,
              "entity_en": "Cilostazol"
            }
          ],
          "relations": [],
          "sentence_en": "Other antiplatelet drugs include aspirin, dipyridamole (perydryl) and cilostazol."
        }
      ],
      "paragraph_en": "Other antiplatelet drugs include aspirin, dipyridamole (perydryl) and cilostazol."
    },
    {
      "paragraph_id": "29",
      "paragraph": "(2)抗凝血药：包括抗凝血因子、抗血小板因子及新型的Xa因子和Ⅱa抑制剂。抗凝血因子又分为非肠道用药及肠道用药，临床常用的肝素(多用低分子肝素)为非肠道用药。新型抗凝血药指新研发上市的口服Xa因子和Ⅱa直接抑制剂，前者包括阿哌沙班、利伐沙班、依度沙班等，后者有达比加群。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(2)抗凝血药：包括抗凝血因子、抗血小板因子及新型的Xa因子和Ⅱa抑制剂。抗凝血因子又分为非肠道用药及肠道用药，临床常用的肝素(多用低分子肝素)为非肠道用药。新型抗凝血药指新研发上市的口服Xa因子和Ⅱa直接抑制剂，前者包括阿哌沙班、利伐沙班、依度沙班等，后者有达比加群。",
          "start_idx": 0,
          "end_idx": 135,
          "entities": [
            {
              "entity_id": "T301",
              "entity": "抗凝血因子",
              "entity_type": "Drug",
              "start_idx": 10,
              "end_idx": 15,
              "entity_en": "Anticoagulant factors"
            },
            {
              "entity_id": "T302",
              "entity": "抗血小板因子",
              "entity_type": "Drug",
              "start_idx": 16,
              "end_idx": 22,
              "entity_en": "Antiplatelet factors"
            },
            {
              "entity_id": "T303",
              "entity": "新型的Xa因子和Ⅱa抑制剂",
              "entity_type": "Drug",
              "start_idx": 23,
              "end_idx": 36,
              "entity_en": "New factor Xa and IIa inhibitors"
            },
            {
              "entity_id": "T304",
              "entity": "抗凝血因子",
              "entity_type": "Drug",
              "start_idx": 37,
              "end_idx": 42,
              "entity_en": "Anticoagulant factors"
            },
            {
              "entity_id": "T305",
              "entity": "肝素(多用低分子肝素)",
              "entity_type": "Drug",
              "start_idx": 61,
              "end_idx": 72,
              "entity_en": "Heparin (mostly low molecular weight heparin)"
            },
            {
              "entity_id": "T306",
              "entity": "Xa因子和Ⅱa直接抑制剂",
              "entity_type": "Drug",
              "start_idx": 94,
              "end_idx": 106,
              "entity_en": "Direct inhibitors of factor Xa and IIa"
            },
            {
              "entity_id": "T307",
              "entity": "阿哌沙班",
              "entity_type": "Drug",
              "start_idx": 111,
              "end_idx": 115,
              "entity_en": "Apixaban"
            },
            {
              "entity_id": "T308",
              "entity": "利伐沙班",
              "entity_type": "Drug",
              "start_idx": 116,
              "end_idx": 120,
              "entity_en": "Rivaroxaban"
            },
            {
              "entity_id": "T309",
              "entity": "依度沙班",
              "entity_type": "Drug",
              "start_idx": 121,
              "end_idx": 125,
              "entity_en": "Edoxaban"
            },
            {
              "entity_id": "T310",
              "entity": "达比加群",
              "entity_type": "Drug",
              "start_idx": 130,
              "end_idx": 134,
              "entity_en": "Dabigatran"
            },
            {
              "entity_id": "T311",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 92,
              "end_idx": 94,
              "entity_en": "oral"
            }
          ],
          "relations": [
            {
              "relation_type": "Method_Drug",
              "relation_id": "R169",
              "head_entity_id": "T311",
              "tail_entity_id": "T306"
            }
          ],
          "sentence_en": "(2) Anticoagulants: including anticoagulant factors, antiplatelet factors, and new Xa factor and IIa inhibitors. Anticoagulant factors are further divided into parenteral and enteral drugs. Commonly used heparin (mostly low molecular weight heparin) is a parenteral drug. New anticoagulants refer to newly developed and marketed oral Xa factor and IIa direct inhibitors. The former include apixaban, rivaroxaban, edoxaban, etc., and the latter include dabigatran."
        }
      ],
      "paragraph_en": "(2) Anticoagulants: including anticoagulant factors, antiplatelet factors, and new Xa factor and IIa inhibitors. Anticoagulant factors are further divided into parenteral and enteral drugs. Commonly used heparin (mostly low molecular weight heparin) is a parenteral drug. New anticoagulants refer to newly developed and marketed oral Xa factor and IIa direct inhibitors. The former include apixaban, rivaroxaban, edoxaban, etc., and the latter include dabigatran."
    },
    {
      "paragraph_id": "30",
      "paragraph": "(3)促纤溶药：蚓激酶是从露天红赤子爱胜蚓中提取的一种含有纤维蛋白溶酶和纤维蛋白溶酶原激活剂的混合物，可用于缺血性心脑血管疾病和糖尿病性周围血管闭塞症。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(3)促纤溶药：蚓激酶是从露天红赤子爱胜蚓中提取的一种含有纤维蛋白溶酶和纤维蛋白溶酶原激活剂的混合物，可用于缺血性心脑血管疾病和糖尿病性周围血管闭塞症。",
          "start_idx": 0,
          "end_idx": 76,
          "entities": [
            {
              "entity_id": "T312",
              "entity": "蚓激酶",
              "entity_type": "Drug",
              "start_idx": 8,
              "end_idx": 11,
              "entity_en": "Lumbrokinase"
            },
            {
              "entity_id": "T313",
              "entity": "缺血性心脑血管疾病",
              "entity_type": "Disease",
              "start_idx": 54,
              "end_idx": 63,
              "entity_en": "Ischemic cardiovascular and cerebrovascular diseases"
            },
            {
              "entity_id": "T314",
              "entity": "糖尿病性周围血管闭塞症",
              "entity_type": "Disease",
              "start_idx": 64,
              "end_idx": 75,
              "entity_en": "Diabetic peripheral vascular occlusive disease"
            },
            {
              "entity_id": "T315",
              "entity": "心脑血管",
              "entity_type": "Anatomy",
              "start_idx": 57,
              "end_idx": 61,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T316",
              "entity": "周围血管",
              "entity_type": "Anatomy",
              "start_idx": 68,
              "end_idx": 72,
              "entity_en": "Peripheral blood vessels"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R170",
              "head_entity_id": "T315",
              "tail_entity_id": "T313"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R171",
              "head_entity_id": "T316",
              "tail_entity_id": "T314"
            }
          ],
          "sentence_en": "(3) Fibrinolytic drugs: Lumbrokinase is a mixture of plasmin and plasminogen activator extracted from the earthworm Eisenia fetida, which can be used for ischemic cardiovascular and cerebrovascular diseases and diabetic peripheral vascular occlusive disease."
        }
      ],
      "paragraph_en": "(3) Fibrinolytic drugs: Lumbrokinase is a mixture of plasmin and plasminogen activator extracted from the earthworm Eisenia fetida, which can be used for ischemic cardiovascular and cerebrovascular diseases and diabetic peripheral vascular occlusive disease."
    },
    {
      "paragraph_id": "31",
      "paragraph": "4.2.3 保护血管内皮的药物",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "4.2.3 保护血管内皮的药物",
          "start_idx": 0,
          "end_idx": 15,
          "entities": [],
          "relations": [],
          "sentence_en": "4.2.3 Drugs that protect the vascular endothelium"
        }
      ],
      "paragraph_en": "4.2.3 Drugs that protect the vascular endothelium"
    },
    {
      "paragraph_id": "32",
      "paragraph": "(1)血管保护药：①羟苯磺酸钙通过抗氧化应激作用，减轻炎症改善血管内皮功能紊乱，减轻微血管渗漏，改善微循环；减少血管内皮生长因子(vascular endothelial growth factor，VEGF)与受体结合，抑制新生血管生成。临床用于治疗糖尿病视网膜病变及糖尿病肾病。一项多中心、随机双盲对照研究证实，伴有早期视网膜病变的2型糖尿病患者使用羟苯磺酸钙治疗24个月，后玻璃体穿透率(posterior vitreous penetration ratio，PVPR)较基线进行性降低(降幅13.2%)，且不同血糖控制水平的亚组中PVPR均有显著改善，微动脉瘤及出血进展平均值均显著低于安慰剂组。一项纳入221项研究的荟萃分析显示，羟苯磺酸钙可显著改善非增殖期视网膜病变患者微动脉瘤、眼底渗出和眼底出血。对于较晚期的视网膜病变患者，羟苯磺酸钙可作为激光治疗的辅助手段，进一步提高激光治疗疗效。中国一项随机临床试验也显示，较单纯视网膜激光治疗组，羟苯磺酸钙联合视网膜激光治疗组能更明显减少糖尿病患者的黄斑中心凹厚度。一项针对糖尿病肾脏病变的观察性研究显示，羟苯磺酸治疗3个月可使90%的糖尿病肾脏病患者微量蛋白尿下降至正常。②递法明主要成分为欧洲越橘的花青苷和β-胡萝卜素。花青苷被认为具有抗氧化、抗炎、抗渗出和抗出血的作用，促进视网膜对光线强度化的敏感性，改善视力、暗适应和视网膜的血液供应，因而能够保护血管、改善微循环。在欧洲，用于临床治疗视网膜病变已多年。中国一项察性研究结果显示，递法明组的单纯型糖尿病网膜病变患者改善情况优于常规组(P<0.05)。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(1)血管保护药：①羟苯磺酸钙通过抗氧化应激作用，减轻炎症改善血管内皮功能紊乱，减轻微血管渗漏，改善微循环；减少血管内皮生长因子(vascular endothelial growth factor，VEGF)与受体结合，抑制新生血管生成。临床用于治疗糖尿病视网膜病变及糖尿病肾病。一项多中心、随机双盲对照研究证实，伴有早期视网膜病变的2型糖尿病患者使用羟苯磺酸钙治疗24个月，后玻璃体穿透率(posterior vitreous penetration ratio，PVPR)较基线进行性降低(降幅13.2%)，且不同血糖控制水平的亚组中PVPR均有显著改善，微动脉瘤及出血进展平均值均显著低于安慰剂组。一项纳入221项研究的荟萃分析显示，羟苯磺酸钙可显著改善非增殖期视网膜病变患者微动脉瘤、眼底渗出和眼底出血。对于较晚期的视网膜病变患者，羟苯磺酸钙可作为激光治疗的辅助手段，进一步提高激光治疗疗效。中国一项随机临床试验也显示，较单纯视网膜激光治疗组，羟苯磺酸钙联合视网膜激光治疗组能更明显减少糖尿病患者的黄斑中心凹厚度。一项针对糖尿病肾脏病变的观察性研究显示，羟苯磺酸治疗3个月可使90%的糖尿病肾脏病患者微量蛋白尿下降至正常。",
          "start_idx": 0,
          "end_idx": 516,
          "entities": [
            {
              "entity_id": "T317",
              "entity": "羟苯磺酸钙",
              "entity_type": "Drug",
              "start_idx": 10,
              "end_idx": 15,
              "entity_en": "Calcium Dobesilate"
            },
            {
              "entity_id": "T318",
              "entity": "羟苯磺酸钙",
              "entity_type": "Drug",
              "start_idx": 177,
              "end_idx": 182,
              "entity_en": "Calcium Dobesilate"
            },
            {
              "entity_id": "T319",
              "entity": "糖尿病视网膜病变",
              "entity_type": "Disease",
              "start_idx": 126,
              "end_idx": 134,
              "entity_en": "Diabetic retinopathy"
            },
            {
              "entity_id": "T320",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 135,
              "end_idx": 140,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T321",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 138,
              "end_idx": 139,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T322",
              "entity": "视网膜",
              "entity_type": "Anatomy",
              "start_idx": 129,
              "end_idx": 132,
              "entity_en": "Retina"
            },
            {
              "entity_id": "T323",
              "entity": "早期视网膜病变",
              "entity_type": "Symptom",
              "start_idx": 160,
              "end_idx": 167,
              "entity_en": "Early retinopathy"
            },
            {
              "entity_id": "T324",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 168,
              "end_idx": 170,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T325",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 168,
              "end_idx": 173,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T326",
              "entity": "玻璃体穿透率(posterior vitreous penetration ratio，PVPR)",
              "entity_type": "Test_items",
              "start_idx": 190,
              "end_idx": 239,
              "entity_en": "Posterior vitreous penetration ratio (PVPR)"
            },
            {
              "entity_id": "T327",
              "entity": "进行性降低(降幅13.2%)",
              "entity_type": "Test_Value",
              "start_idx": 242,
              "end_idx": 256,
              "entity_en": "Progressive decrease (decreased by 13.2%)"
            },
            {
              "entity_id": "T328",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 260,
              "end_idx": 262,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T329",
              "entity": "微动脉瘤",
              "entity_type": "Disease",
              "start_idx": 281,
              "end_idx": 285,
              "entity_en": "Microaneurysm"
            },
            {
              "entity_id": "T330",
              "entity": "羟苯磺酸钙",
              "entity_type": "Drug",
              "start_idx": 321,
              "end_idx": 326,
              "entity_en": "Calcium Dobesilate"
            },
            {
              "entity_id": "T331",
              "entity": "非增殖期",
              "entity_type": "Class",
              "start_idx": 331,
              "end_idx": 335,
              "entity_en": "Non-proliferative phase"
            },
            {
              "entity_id": "T332",
              "entity": "视网膜病变",
              "entity_type": "Disease",
              "start_idx": 335,
              "end_idx": 340,
              "entity_en": "Retinopathy"
            },
            {
              "entity_id": "T333",
              "entity": "视网膜",
              "entity_type": "Anatomy",
              "start_idx": 335,
              "end_idx": 338,
              "entity_en": "Retina"
            },
            {
              "entity_id": "T334",
              "entity": "微动脉瘤",
              "entity_type": "Symptom",
              "start_idx": 342,
              "end_idx": 346,
              "entity_en": "Microaneurysm"
            },
            {
              "entity_id": "T335",
              "entity": "眼底渗出",
              "entity_type": "Symptom",
              "start_idx": 347,
              "end_idx": 351,
              "entity_en": "Fundus exudation"
            },
            {
              "entity_id": "T336",
              "entity": "眼底出血",
              "entity_type": "Symptom",
              "start_idx": 352,
              "end_idx": 356,
              "entity_en": "Retinal hemorrhage"
            },
            {
              "entity_id": "T337",
              "entity": "晚期",
              "entity_type": "Class",
              "start_idx": 360,
              "end_idx": 362,
              "entity_en": "Late stage"
            },
            {
              "entity_id": "T338",
              "entity": "视网膜病变",
              "entity_type": "Disease",
              "start_idx": 363,
              "end_idx": 368,
              "entity_en": "Retinopathy"
            },
            {
              "entity_id": "T339",
              "entity": "羟苯磺酸钙",
              "entity_type": "Drug",
              "start_idx": 371,
              "end_idx": 376,
              "entity_en": "Calcium Dobesilate"
            },
            {
              "entity_id": "T340",
              "entity": "激光治疗",
              "entity_type": "Treatment",
              "start_idx": 379,
              "end_idx": 383,
              "entity_en": "Laser therapy"
            },
            {
              "entity_id": "T341",
              "entity": "激光治疗",
              "entity_type": "Treatment",
              "start_idx": 394,
              "end_idx": 398,
              "entity_en": "Laser therapy"
            },
            {
              "entity_id": "T342",
              "entity": "视网膜激光治疗",
              "entity_type": "Treatment",
              "start_idx": 418,
              "end_idx": 425,
              "entity_en": "Retinal laser treatment"
            },
            {
              "entity_id": "T343",
              "entity": "羟苯磺酸钙",
              "entity_type": "Drug",
              "start_idx": 427,
              "end_idx": 432,
              "entity_en": "Calcium Dobesilate"
            },
            {
              "entity_id": "T344",
              "entity": "视网膜激光治疗",
              "entity_type": "Treatment",
              "start_idx": 434,
              "end_idx": 441,
              "entity_en": "Retinal laser treatment"
            },
            {
              "entity_id": "T345",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 448,
              "end_idx": 451,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T346",
              "entity": "黄斑中心凹厚度",
              "entity_type": "Test_items",
              "start_idx": 454,
              "end_idx": 461,
              "entity_en": "Foveal thickness"
            },
            {
              "entity_id": "T347",
              "entity": "糖尿病肾脏病变",
              "entity_type": "Disease",
              "start_idx": 466,
              "end_idx": 473,
              "entity_en": "Diabetic Nephropathy"
            },
            {
              "entity_id": "T348",
              "entity": "肾脏",
              "entity_type": "Anatomy",
              "start_idx": 469,
              "end_idx": 471,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T349",
              "entity": "羟苯磺酸",
              "entity_type": "Drug",
              "start_idx": 482,
              "end_idx": 486,
              "entity_en": "Dobesilic acid"
            },
            {
              "entity_id": "T350",
              "entity": "糖尿病肾脏病",
              "entity_type": "Disease",
              "start_idx": 497,
              "end_idx": 503,
              "entity_en": "Diabetic kidney disease"
            },
            {
              "entity_id": "T351",
              "entity": "肾脏",
              "entity_type": "Anatomy",
              "start_idx": 500,
              "end_idx": 502,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T352",
              "entity": "蛋白尿",
              "entity_type": "Test_items",
              "start_idx": 507,
              "end_idx": 510,
              "entity_en": "Proteinuria"
            },
            {
              "entity_id": "T353",
              "entity": "下降至正常",
              "entity_type": "Test_Value",
              "start_idx": 510,
              "end_idx": 515,
              "entity_en": "Down to normal"
            },
            {
              "entity_id": "T354",
              "entity": "3个月",
              "entity_type": "Duration",
              "start_idx": 488,
              "end_idx": 491,
              "entity_en": "3 months"
            },
            {
              "entity_id": "T362",
              "entity": "视网膜",
              "entity_type": "Anatomy",
              "start_idx": 363,
              "end_idx": 366,
              "entity_en": "Retina"
            },
            {
              "entity_id": "T363",
              "entity": "24个月",
              "entity_type": "Duration",
              "start_idx": 184,
              "end_idx": 188,
              "entity_en": "24 months"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R172",
              "head_entity_id": "T317",
              "tail_entity_id": "T319"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R173",
              "head_entity_id": "T317",
              "tail_entity_id": "T320"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R174",
              "head_entity_id": "T318",
              "tail_entity_id": "T325"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R175",
              "head_entity_id": "T363",
              "tail_entity_id": "T318"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R176",
              "head_entity_id": "T322",
              "tail_entity_id": "T319"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R177",
              "head_entity_id": "T321",
              "tail_entity_id": "T320"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R178",
              "head_entity_id": "T323",
              "tail_entity_id": "T325"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R179",
              "head_entity_id": "T324",
              "tail_entity_id": "T325"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R180",
              "head_entity_id": "T326",
              "tail_entity_id": "T325"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R181",
              "head_entity_id": "T328",
              "tail_entity_id": "T325"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R182",
              "head_entity_id": "T330",
              "tail_entity_id": "T332"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R183",
              "head_entity_id": "T331",
              "tail_entity_id": "T332"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R184",
              "head_entity_id": "T333",
              "tail_entity_id": "T332"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R185",
              "head_entity_id": "T334",
              "tail_entity_id": "T332"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R186",
              "head_entity_id": "T335",
              "tail_entity_id": "T332"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R187",
              "head_entity_id": "T336",
              "tail_entity_id": "T332"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R188",
              "head_entity_id": "T337",
              "tail_entity_id": "T338"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R189",
              "head_entity_id": "T362",
              "tail_entity_id": "T338"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R190",
              "head_entity_id": "T339",
              "tail_entity_id": "T338"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R191",
              "head_entity_id": "T340",
              "tail_entity_id": "T338"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R192",
              "head_entity_id": "T341",
              "tail_entity_id": "T338"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R193",
              "head_entity_id": "T342",
              "tail_entity_id": "T345"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R194",
              "head_entity_id": "T343",
              "tail_entity_id": "T345"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R195",
              "head_entity_id": "T346",
              "tail_entity_id": "T345"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R196",
              "head_entity_id": "T348",
              "tail_entity_id": "T347"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R197",
              "head_entity_id": "T349",
              "tail_entity_id": "T347"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R198",
              "head_entity_id": "T354",
              "tail_entity_id": "T349"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R199",
              "head_entity_id": "T351",
              "tail_entity_id": "T350"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R200",
              "head_entity_id": "T352",
              "tail_entity_id": "T350"
            }
          ],
          "sentence_en": "(1) Vascular protective drugs: ① Calcium dobesilate can reduce inflammation, improve endothelial dysfunction, reduce microvascular leakage, and improve microcirculation through anti-oxidative stress; it can reduce the binding of vascular endothelial growth factor (VEGF) to receptors and inhibit angiogenesis. It is clinically used to treat diabetic retinopathy and diabetic nephropathy. A multicenter, randomized, double-blind controlled study confirmed that in patients with type 2 diabetes and early retinopathy treated with calcium dobesilate for 24 months, the posterior vitreous penetration ratio (PVPR) was progressively reduced compared with the baseline (a decrease of 13.2%), and the PVPR was significantly improved in subgroups with different blood sugar control levels. The average values of microaneurysms and hemorrhage progression were significantly lower than those in the placebo group. A meta-analysis of 221 studies showed that calcium dobesilate can significantly improve microaneurysms, fundus exudation, and fundus hemorrhage in patients with non-proliferative retinopathy. For patients with more advanced retinopathy, calcium dobesilate can be used as an adjuvant to laser treatment to further improve the efficacy of laser treatment. A randomized clinical trial in China also showed that calcium dobesilate combined with retinal laser treatment can significantly reduce the thickness of the fovea of diabetic patients compared with the retinal laser treatment group alone. An observational study on diabetic nephropathy showed that 3 months of dobesilate treatment can reduce microalbuminuria to normal in 90% of diabetic nephropathy patients."
        },
        {
          "sentence_id": "1",
          "sentence": "②递法明主要成分为欧洲越橘的花青苷和β-胡萝卜素。",
          "start_idx": 516,
          "end_idx": 541,
          "entities": [
            {
              "entity_id": "T355",
              "entity": "递法明",
              "entity_type": "Drug",
              "start_idx": 1,
              "end_idx": 4,
              "entity_en": "Difamin"
            }
          ],
          "relations": [],
          "sentence_en": "②The main ingredients of Defamin are anthocyanins and β-carotene from European bilberry."
        },
        {
          "sentence_id": "2",
          "sentence": "花青苷被认为具有抗氧化、抗炎、抗渗出和抗出血的作用，促进视网膜对光线强度化的敏感性，改善视力、暗适应和视网膜的血液供应，因而能够保护血管、改善微循环。",
          "start_idx": 541,
          "end_idx": 616,
          "entities": [],
          "relations": [],
          "sentence_en": "Anthocyanins are believed to have antioxidant, anti-inflammatory, anti-exudative and anti-hemorrhagic effects, promote the sensitivity of the retina to increased light intensity, improve vision, dark adaptation and retinal blood supply, thereby protecting blood vessels and improving microcirculation."
        },
        {
          "sentence_id": "3",
          "sentence": "在欧洲，用于临床治疗视网膜病变已多年。",
          "start_idx": 616,
          "end_idx": 635,
          "entities": [
            {
              "entity_id": "T356",
              "entity": "视网膜病变",
              "entity_type": "Disease",
              "start_idx": 10,
              "end_idx": 15,
              "entity_en": "Retinopathy"
            },
            {
              "entity_id": "T357",
              "entity": "视网膜",
              "entity_type": "Anatomy",
              "start_idx": 10,
              "end_idx": 13,
              "entity_en": "Retina"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R201",
              "head_entity_id": "T357",
              "tail_entity_id": "T356"
            }
          ],
          "sentence_en": "In Europe, it has been used in clinical treatment of retinopathy for many years."
        },
        {
          "sentence_id": "4",
          "sentence": "中国一项察性研究结果显示，递法明组的单纯型糖尿病网膜病变患者改善情况优于常规组(P<0.05)。",
          "start_idx": 635,
          "end_idx": 683,
          "entities": [
            {
              "entity_id": "T358",
              "entity": "递法明",
              "entity_type": "Drug",
              "start_idx": 13,
              "end_idx": 16,
              "entity_en": "Difamin"
            },
            {
              "entity_id": "T359",
              "entity": "单纯型",
              "entity_type": "Class",
              "start_idx": 18,
              "end_idx": 21,
              "entity_en": "Simple type"
            },
            {
              "entity_id": "T360",
              "entity": "糖尿病网膜病变",
              "entity_type": "Disease",
              "start_idx": 21,
              "end_idx": 28,
              "entity_en": "Diabetic retinopathy"
            },
            {
              "entity_id": "T361",
              "entity": "网膜",
              "entity_type": "Anatomy",
              "start_idx": 24,
              "end_idx": 26,
              "entity_en": "Omentum"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R202",
              "head_entity_id": "T358",
              "tail_entity_id": "T360"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R203",
              "head_entity_id": "T359",
              "tail_entity_id": "T360"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R204",
              "head_entity_id": "T361",
              "tail_entity_id": "T360"
            }
          ],
          "sentence_en": "The results of a Chinese observational study showed that the improvement of patients with simple diabetic retinopathy in the difabulin group was better than that in the conventional group (P<0.05)."
        }
      ],
      "paragraph_en": "(1) Vascular protective drugs: ① Calcium dobesilate can reduce inflammation, improve endothelial dysfunction, reduce microvascular leakage, and improve microcirculation through anti-oxidative stress; it can reduce the binding of vascular endothelial growth factor (VEGF) to receptors and inhibit angiogenesis. It is clinically used to treat diabetic retinopathy and diabetic nephropathy. A multicenter, randomized, double-blind controlled study confirmed that in patients with type 2 diabetes and early retinopathy treated with calcium dobesilate for 24 months, the posterior vitreous penetration ratio (PVPR) was progressively reduced compared with the baseline (a decrease of 13.2%), and the PVPR was significantly improved in subgroups with different blood sugar control levels. The average values of microaneurysms and hemorrhage progression were significantly lower than those in the placebo group. A meta-analysis of 221 studies showed that calcium dobesilate can significantly improve microaneurysms, fundus exudation, and fundus hemorrhage in patients with non-proliferative retinopathy. For patients with more advanced retinopathy, calcium dobesilate can be used as an adjuvant to laser treatment to further improve the efficacy of laser treatment. A randomized clinical trial in China also showed that calcium dobesilate combined with retinal laser treatment could significantly reduce the foveal thickness of diabetic patients compared with the simple retinal laser treatment group. An observational study on diabetic nephropathy showed that 3 months of dobesilate treatment could reduce microalbuminuria to normal in 90% of patients with diabetic nephropathy. ② The main components of Defamin are anthocyanins and β-carotene from bilberry. Anthocyanins are believed to have antioxidant, anti-inflammatory, anti-exudative and anti-hemorrhagic effects, promote the sensitivity of the retina to light intensity, improve vision, dark adaptation and retinal blood supply, and thus protect blood vessels and improve microcirculation. In Europe, it has been used for clinical treatment of retinopathy for many years. The results of an observational study in China showed that the improvement of patients with simple diabetic retinopathy in the Defamin group was better than that in the conventional group (P<0.05)."
    },
    {
      "paragraph_id": "33",
      "paragraph": "(2)抗血管内皮生长因子药：①雷珠单抗，临床上用于各种原因引起的黄斑水肿、视网膜新生血管、视网膜静脉阻塞、新生血管性青光眼等疾病。随机对照研究结果显示，雷珠单抗可显著降低糖尿病黄斑水肿患者硬性渗出区域。此外，存在黄斑水肿、黄斑变性、视网膜内囊肿、玻璃体严重增厚眼病的糖尿病患者使用雷珠单抗治疗可有效减轻黄斑变性。②贝伐单抗可用于治疗视网膜新生血管性疾病。一项随机对照研究结果显示，贝伐单抗联合视网膜光凝术治疗可显著降低高风险糖尿病视网膜病变患者的视敏度恶化程度，减少黄斑中心凹厚度及黄斑体积。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(2)抗血管内皮生长因子药：①雷珠单抗，临床上用于各种原因引起的黄斑水肿、视网膜新生血管、视网膜静脉阻塞、新生血管性青光眼等疾病。随机对照研究结果显示，雷珠单抗可显著降低糖尿病黄斑水肿患者硬性渗出区域。此外，存在黄斑水肿、黄斑变性、视网膜内囊肿、玻璃体严重增厚眼病的糖尿病患者使用雷珠单抗治疗可有效减轻黄斑变性。②贝伐单抗可用于治疗视网膜新生血管性疾病。一项随机对照研究结果显示，贝伐单抗联合视网膜光凝术治疗可显著降低高风险糖尿病视网膜病变患者的视敏度恶化程度，减少黄斑中心凹厚度及黄斑体积。",
          "start_idx": 0,
          "end_idx": 246,
          "entities": [
            {
              "entity_id": "T364",
              "entity": "雷珠单抗",
              "entity_type": "Drug",
              "start_idx": 15,
              "end_idx": 19,
              "entity_en": "Ranibizumab"
            },
            {
              "entity_id": "T365",
              "entity": "黄斑水肿",
              "entity_type": "Disease",
              "start_idx": 32,
              "end_idx": 36,
              "entity_en": "Macular edema"
            },
            {
              "entity_id": "T366",
              "entity": "黄斑",
              "entity_type": "Anatomy",
              "start_idx": 32,
              "end_idx": 34,
              "entity_en": "Macula"
            },
            {
              "entity_id": "T367",
              "entity": "视网膜新生血管",
              "entity_type": "Disease",
              "start_idx": 37,
              "end_idx": 44,
              "entity_en": "Retinal neovascularization"
            },
            {
              "entity_id": "T368",
              "entity": "视网膜",
              "entity_type": "Anatomy",
              "start_idx": 37,
              "end_idx": 40,
              "entity_en": "Retina"
            },
            {
              "entity_id": "T369",
              "entity": "视网膜静脉阻塞",
              "entity_type": "Disease",
              "start_idx": 45,
              "end_idx": 52,
              "entity_en": "Retinal vein occlusion"
            },
            {
              "entity_id": "T370",
              "entity": "视网膜",
              "entity_type": "Anatomy",
              "start_idx": 45,
              "end_idx": 48,
              "entity_en": "Retina"
            },
            {
              "entity_id": "T371",
              "entity": "新生血管性青光眼",
              "entity_type": "Disease",
              "start_idx": 53,
              "end_idx": 61,
              "entity_en": "Neovascular glaucoma"
            },
            {
              "entity_id": "T372",
              "entity": "眼",
              "entity_type": "Anatomy",
              "start_idx": 60,
              "end_idx": 61,
              "entity_en": "Eye"
            },
            {
              "entity_id": "T373",
              "entity": "雷珠单抗",
              "entity_type": "Drug",
              "start_idx": 76,
              "end_idx": 80,
              "entity_en": "Ranibizumab"
            },
            {
              "entity_id": "T374",
              "entity": "黄斑水肿",
              "entity_type": "Disease",
              "start_idx": 106,
              "end_idx": 110,
              "entity_en": "Macular edema"
            },
            {
              "entity_id": "T375",
              "entity": "糖尿病黄斑水肿",
              "entity_type": "Disease",
              "start_idx": 85,
              "end_idx": 92,
              "entity_en": "Diabetic Macular Edema"
            },
            {
              "entity_id": "T376",
              "entity": "黄斑",
              "entity_type": "Anatomy",
              "start_idx": 88,
              "end_idx": 90,
              "entity_en": "Macula"
            },
            {
              "entity_id": "T377",
              "entity": "黄斑变性",
              "entity_type": "Disease",
              "start_idx": 111,
              "end_idx": 115,
              "entity_en": "Macular degeneration"
            },
            {
              "entity_id": "T378",
              "entity": "视网膜内囊肿",
              "entity_type": "Disease",
              "start_idx": 116,
              "end_idx": 122,
              "entity_en": "Intraretinal cyst"
            },
            {
              "entity_id": "T379",
              "entity": "玻璃体严重增厚眼病",
              "entity_type": "Disease",
              "start_idx": 123,
              "end_idx": 132,
              "entity_en": "Severe vitreous thickening"
            },
            {
              "entity_id": "T380",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 133,
              "end_idx": 136,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T381",
              "entity": "雷珠单抗",
              "entity_type": "Drug",
              "start_idx": 140,
              "end_idx": 144,
              "entity_en": "Ranibizumab"
            },
            {
              "entity_id": "T382",
              "entity": "黄斑变性",
              "entity_type": "Disease",
              "start_idx": 151,
              "end_idx": 155,
              "entity_en": "Macular degeneration"
            },
            {
              "entity_id": "T383",
              "entity": "黄斑",
              "entity_type": "Anatomy",
              "start_idx": 106,
              "end_idx": 108,
              "entity_en": "Macula"
            },
            {
              "entity_id": "T384",
              "entity": "黄斑",
              "entity_type": "Anatomy",
              "start_idx": 111,
              "end_idx": 113,
              "entity_en": "Macula"
            },
            {
              "entity_id": "T385",
              "entity": "视网膜",
              "entity_type": "Anatomy",
              "start_idx": 116,
              "end_idx": 119,
              "entity_en": "Retina"
            },
            {
              "entity_id": "T386",
              "entity": "玻璃体",
              "entity_type": "Anatomy",
              "start_idx": 123,
              "end_idx": 126,
              "entity_en": "Vitreous"
            },
            {
              "entity_id": "T387",
              "entity": "黄斑",
              "entity_type": "Anatomy",
              "start_idx": 151,
              "end_idx": 153,
              "entity_en": "Macula"
            },
            {
              "entity_id": "T388",
              "entity": "贝伐单抗",
              "entity_type": "Drug",
              "start_idx": 157,
              "end_idx": 161,
              "entity_en": "Bevacizumab"
            },
            {
              "entity_id": "T389",
              "entity": "视网膜新生血管性疾病",
              "entity_type": "Disease",
              "start_idx": 166,
              "end_idx": 176,
              "entity_en": "Retinal neovascular disease"
            },
            {
              "entity_id": "T390",
              "entity": "视网膜",
              "entity_type": "Anatomy",
              "start_idx": 166,
              "end_idx": 169,
              "entity_en": "Retina"
            },
            {
              "entity_id": "T391",
              "entity": "贝伐单抗",
              "entity_type": "Drug",
              "start_idx": 190,
              "end_idx": 194,
              "entity_en": "Bevacizumab"
            },
            {
              "entity_id": "T392",
              "entity": "视网膜光凝术治疗",
              "entity_type": "Operation",
              "start_idx": 196,
              "end_idx": 204,
              "entity_en": "Retinal photocoagulation therapy"
            },
            {
              "entity_id": "T393",
              "entity": "糖尿病视网膜病变",
              "entity_type": "Disease",
              "start_idx": 212,
              "end_idx": 220,
              "entity_en": "Diabetic retinopathy"
            },
            {
              "entity_id": "T394",
              "entity": "视网膜",
              "entity_type": "Anatomy",
              "start_idx": 215,
              "end_idx": 218,
              "entity_en": "Retina"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R205",
              "head_entity_id": "T364",
              "tail_entity_id": "T365"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R206",
              "head_entity_id": "T364",
              "tail_entity_id": "T367"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R207",
              "head_entity_id": "T364",
              "tail_entity_id": "T369"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R208",
              "head_entity_id": "T364",
              "tail_entity_id": "T371"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R209",
              "head_entity_id": "T366",
              "tail_entity_id": "T365"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R210",
              "head_entity_id": "T368",
              "tail_entity_id": "T367"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R211",
              "head_entity_id": "T370",
              "tail_entity_id": "T369"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R212",
              "head_entity_id": "T372",
              "tail_entity_id": "T371"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R213",
              "head_entity_id": "T373",
              "tail_entity_id": "T375"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R214",
              "head_entity_id": "T381",
              "tail_entity_id": "T374"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R215",
              "head_entity_id": "T383",
              "tail_entity_id": "T374"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R216",
              "head_entity_id": "T376",
              "tail_entity_id": "T375"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R217",
              "head_entity_id": "T381",
              "tail_entity_id": "T377"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R218",
              "head_entity_id": "T384",
              "tail_entity_id": "T377"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R219",
              "head_entity_id": "T381",
              "tail_entity_id": "T378"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R220",
              "head_entity_id": "T385",
              "tail_entity_id": "T378"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R221",
              "head_entity_id": "T381",
              "tail_entity_id": "T379"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R222",
              "head_entity_id": "T386",
              "tail_entity_id": "T379"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R223",
              "head_entity_id": "T381",
              "tail_entity_id": "T382"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R224",
              "head_entity_id": "T387",
              "tail_entity_id": "T382"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R225",
              "head_entity_id": "T388",
              "tail_entity_id": "T389"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R226",
              "head_entity_id": "T390",
              "tail_entity_id": "T389"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R227",
              "head_entity_id": "T391",
              "tail_entity_id": "T393"
            },
            {
              "relation_type": "Operation_Disease",
              "relation_id": "R228",
              "head_entity_id": "T392",
              "tail_entity_id": "T393"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R229",
              "head_entity_id": "T394",
              "tail_entity_id": "T393"
            }
          ],
          "sentence_en": "(2) Anti-vascular endothelial growth factor drugs: ① Ranibizumab is clinically used for macular edema, retinal neovascularization, retinal vein occlusion, neovascular glaucoma and other diseases caused by various reasons. The results of randomized controlled studies have shown that ranibizumab can significantly reduce the area of hard exudates in patients with diabetic macular edema. In addition, ranibizumab treatment can effectively reduce macular degeneration in diabetic patients with macular edema, macular degeneration, intraretinal cysts, and severe vitreous thickening. ② Bevacizumab can be used to treat retinal neovascular diseases. The results of a randomized controlled study showed that bevacizumab combined with retinal photocoagulation can significantly reduce the deterioration of visual acuity in high-risk patients with diabetic retinopathy, and reduce the thickness of the fovea and macular volume."
        }
      ],
      "paragraph_en": "(2) Anti-vascular endothelial growth factor drugs: ① Ranibizumab is clinically used for macular edema, retinal neovascularization, retinal vein occlusion, neovascular glaucoma and other diseases caused by various reasons. The results of randomized controlled studies have shown that ranibizumab can significantly reduce the area of hard exudates in patients with diabetic macular edema. In addition, ranibizumab treatment can effectively reduce macular degeneration in diabetic patients with macular edema, macular degeneration, intraretinal cysts, and severe vitreous thickening. ② Bevacizumab can be used to treat retinal neovascular diseases. The results of a randomized controlled study showed that bevacizumab combined with retinal photocoagulation can significantly reduce the deterioration of visual acuity in high-risk patients with diabetic retinopathy, and reduce the thickness of the fovea and macular volume."
    },
    {
      "paragraph_id": "34",
      "paragraph": "4.2.4 中药制剂一些具有活血化瘀作用的植物药及中药制剂也常被用于糖尿病微循环障碍的治疗，如银杏叶制剂、复方丹参滴丸、三七制剂等。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "4.2.4 中药制剂一些具有活血化瘀作用的植物药及中药制剂也常被用于糖尿病微循环障碍的治疗，如银杏叶制剂、复方丹参滴丸、三七制剂等。",
          "start_idx": 0,
          "end_idx": 66,
          "entities": [
            {
              "entity_id": "T395",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 34,
              "end_idx": 37,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T396",
              "entity": "微循环障碍",
              "entity_type": "Symptom",
              "start_idx": 37,
              "end_idx": 42,
              "entity_en": "Microcirculatory disorders"
            },
            {
              "entity_id": "T397",
              "entity": "银杏叶制剂",
              "entity_type": "Drug",
              "start_idx": 47,
              "end_idx": 52,
              "entity_en": "Ginkgo biloba preparations"
            },
            {
              "entity_id": "T398",
              "entity": "复方丹参滴丸",
              "entity_type": "Drug",
              "start_idx": 53,
              "end_idx": 59,
              "entity_en": "Compound Danshen Dripping Pills"
            },
            {
              "entity_id": "T399",
              "entity": "三七制剂",
              "entity_type": "Drug",
              "start_idx": 60,
              "end_idx": 64,
              "entity_en": "Panax notoginseng preparations"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R230",
              "head_entity_id": "T397",
              "tail_entity_id": "T395"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R231",
              "head_entity_id": "T398",
              "tail_entity_id": "T395"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R232",
              "head_entity_id": "T399",
              "tail_entity_id": "T395"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R233",
              "head_entity_id": "T396",
              "tail_entity_id": "T395"
            }
          ],
          "sentence_en": "4.2.4 Chinese herbal medicines Some botanical medicines and Chinese herbal medicines with blood-activating and blood-stasis-removing effects are also often used in the treatment of diabetic microcirculatory disorders, such as ginkgo leaf preparations, compound danshen dripping pills, and Panax notoginseng preparations."
        }
      ],
      "paragraph_en": "4.2.4 Chinese herbal medicines Some botanical medicines and Chinese herbal medicines with blood-activating and blood-stasis-removing effects are also often used in the treatment of diabetic microcirculatory disorders, such as ginkgo leaf preparations, compound danshen dripping pills, and Panax notoginseng preparations."
    },
    {
      "paragraph_id": "35",
      "paragraph": "(1)银杏叶提取物片(EGb761)：该药的多成分之间具有协同作用，主要通过降低血液黏度来改善血液流变学，从而改善血液循环；清除自由基，抑制细胞膜发生脂质过氧化；拮抗血小板活化因子(platelet active factor，PAF)，从而抑制血小板聚集；促进突触重塑，保护神经细胞。临床上主要用于脑动脉硬化导致的脑功能障碍、糖尿病性视网病变以及周围血管病变导致的间歇性跛行。脑部、周围血流循环障碍：包括糖尿病引起的视网膜病变及神经障碍、老年黄斑变性、间歇性跛行症等。一项针对台湾地区居民的研究显示，银杏叶提取物片能够有效地改善2型糖尿病视网膜病变患者的视网膜毛细血管血流量，从而缓解糖尿病视网膜病变。系统性评价结果显示，在常规治疗基础上联合银杏叶提取物片可进一步降低糖尿病肾病患空腹血糖及尿白蛋白排泄率，改善患者血液流变学。国内的研究显示，银杏叶提取物片联合甲钴胺治疗糖尿病周围神经病变，可明显改善糖尿周围神经病变患者的临床症状及神经传导速度，总有效率(显效和有效)达到88.9%。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(1)银杏叶提取物片(EGb761)：该药的多成分之间具有协同作用，主要通过降低血液黏度来改善血液流变学，从而改善血液循环；清除自由基，抑制细胞膜发生脂质过氧化；拮抗血小板活化因子(platelet active factor，PAF)，从而抑制血小板聚集；促进突触重塑，保护神经细胞。临床上主要用于脑动脉硬化导致的脑功能障碍、糖尿病性视网病变以及周围血管病变导致的间歇性跛行。脑部、周围血流循环障碍：包括糖尿病引起的视网膜病变及神经障碍、老年黄斑变性、间歇性跛行症等。一项针对台湾地区居民的研究显示，银杏叶提取物片能够有效地改善2型糖尿病视网膜病变患者的视网膜毛细血管血流量，从而缓解糖尿病视网膜病变。系统性评价结果显示，在常规治疗基础上联合银杏叶提取物片可进一步降低糖尿病肾病患空腹血糖及尿白蛋白排泄率，改善患者血液流变学。国内的研究显示，银杏叶提取物片联合甲钴胺治疗糖尿病周围神经病变，可明显改善糖尿周围神经病变患者的临床症状及神经传导速度，总有效率(显效和有效)达到88.9%。",
          "start_idx": 0,
          "end_idx": 443,
          "entities": [
            {
              "entity_id": "T400",
              "entity": "银杏叶提取物片(EGb761)",
              "entity_type": "Drug",
              "start_idx": 3,
              "end_idx": 18,
              "entity_en": "Ginkgo biloba extract tablets (EGb761)"
            },
            {
              "entity_id": "T401",
              "entity": "脑动脉硬化",
              "entity_type": "Disease",
              "start_idx": 150,
              "end_idx": 155,
              "entity_en": "Cerebral arteriosclerosis"
            },
            {
              "entity_id": "T402",
              "entity": "脑功能障碍",
              "entity_type": "Disease",
              "start_idx": 158,
              "end_idx": 163,
              "entity_en": "Brain dysfunction"
            },
            {
              "entity_id": "T403",
              "entity": "糖尿病性视网病变",
              "entity_type": "Disease",
              "start_idx": 164,
              "end_idx": 172,
              "entity_en": "Diabetic Retinopathy"
            },
            {
              "entity_id": "T404",
              "entity": "周围血管病变",
              "entity_type": "Disease",
              "start_idx": 174,
              "end_idx": 180,
              "entity_en": "Peripheral vascular disease"
            },
            {
              "entity_id": "T405",
              "entity": "间歇性跛行",
              "entity_type": "Disease",
              "start_idx": 183,
              "end_idx": 188,
              "entity_en": "Intermittent claudication"
            },
            {
              "entity_id": "T406",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 203,
              "end_idx": 206,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T407",
              "entity": "神经障碍",
              "entity_type": "Disease",
              "start_idx": 215,
              "end_idx": 219,
              "entity_en": "Neurological disorders"
            },
            {
              "entity_id": "T408",
              "entity": "老年黄斑变性",
              "entity_type": "Disease",
              "start_idx": 220,
              "end_idx": 226,
              "entity_en": "Age-related macular degeneration"
            },
            {
              "entity_id": "T409",
              "entity": "间歇性跛行症",
              "entity_type": "Disease",
              "start_idx": 227,
              "end_idx": 233,
              "entity_en": "Intermittent claudication"
            },
            {
              "entity_id": "T410",
              "entity": "2型糖尿病视网膜病变",
              "entity_type": "Disease",
              "start_idx": 265,
              "end_idx": 275,
              "entity_en": "Type 2 diabetic retinopathy"
            },
            {
              "entity_id": "T411",
              "entity": "糖尿病视网膜病变",
              "entity_type": "Disease",
              "start_idx": 293,
              "end_idx": 301,
              "entity_en": "Diabetic retinopathy"
            },
            {
              "entity_id": "T412",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 335,
              "end_idx": 340,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T413",
              "entity": "糖尿病周围神经病变",
              "entity_type": "Disease",
              "start_idx": 386,
              "end_idx": 395,
              "entity_en": "Diabetic peripheral neuropathy"
            },
            {
              "entity_id": "T414",
              "entity": "糖尿周围神经病变",
              "entity_type": "Disease",
              "start_idx": 401,
              "end_idx": 409,
              "entity_en": "Diabetic peripheral neuropathy"
            },
            {
              "entity_id": "T415",
              "entity": "脑动脉",
              "entity_type": "Anatomy",
              "start_idx": 150,
              "end_idx": 153,
              "entity_en": "Cerebral arteries"
            },
            {
              "entity_id": "T416",
              "entity": "脑",
              "entity_type": "Anatomy",
              "start_idx": 158,
              "end_idx": 159,
              "entity_en": "brain"
            },
            {
              "entity_id": "T417",
              "entity": "视网",
              "entity_type": "Anatomy",
              "start_idx": 168,
              "end_idx": 170,
              "entity_en": "Vision Network"
            },
            {
              "entity_id": "T418",
              "entity": "周围血管",
              "entity_type": "Anatomy",
              "start_idx": 174,
              "end_idx": 178,
              "entity_en": "Peripheral blood vessels"
            },
            {
              "entity_id": "T419",
              "entity": "视网膜病变",
              "entity_type": "Disease",
              "start_idx": 209,
              "end_idx": 214,
              "entity_en": "Retinopathy"
            },
            {
              "entity_id": "T420",
              "entity": "视网膜",
              "entity_type": "Anatomy",
              "start_idx": 209,
              "end_idx": 212,
              "entity_en": "Retina"
            },
            {
              "entity_id": "T421",
              "entity": "神经",
              "entity_type": "Anatomy",
              "start_idx": 215,
              "end_idx": 217,
              "entity_en": "nerve"
            },
            {
              "entity_id": "T422",
              "entity": "黄斑",
              "entity_type": "Anatomy",
              "start_idx": 222,
              "end_idx": 224,
              "entity_en": "Macula"
            },
            {
              "entity_id": "T423",
              "entity": "视网膜",
              "entity_type": "Anatomy",
              "start_idx": 270,
              "end_idx": 273,
              "entity_en": "Retina"
            },
            {
              "entity_id": "T424",
              "entity": "视网膜",
              "entity_type": "Anatomy",
              "start_idx": 296,
              "end_idx": 299,
              "entity_en": "Retina"
            },
            {
              "entity_id": "T425",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 338,
              "end_idx": 339,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T426",
              "entity": "周围神经",
              "entity_type": "Anatomy",
              "start_idx": 389,
              "end_idx": 393,
              "entity_en": "Peripheral nerves"
            },
            {
              "entity_id": "T427",
              "entity": "周围神经",
              "entity_type": "Anatomy",
              "start_idx": 403,
              "end_idx": 407,
              "entity_en": "Peripheral nerves"
            },
            {
              "entity_id": "T428",
              "entity": "银杏叶提取物片",
              "entity_type": "Drug",
              "start_idx": 251,
              "end_idx": 258,
              "entity_en": "Ginkgo biloba extract tablets"
            },
            {
              "entity_id": "T429",
              "entity": "银杏叶提取物片",
              "entity_type": "Drug",
              "start_idx": 322,
              "end_idx": 329,
              "entity_en": "Ginkgo biloba extract tablets"
            },
            {
              "entity_id": "T430",
              "entity": "银杏叶提取物片",
              "entity_type": "Drug",
              "start_idx": 372,
              "end_idx": 379,
              "entity_en": "Ginkgo biloba extract tablets"
            },
            {
              "entity_id": "T431",
              "entity": "甲钴胺",
              "entity_type": "Drug",
              "start_idx": 381,
              "end_idx": 384,
              "entity_en": "Methylcobalamin"
            },
            {
              "entity_id": "T432",
              "entity": "空腹血糖",
              "entity_type": "Test_items",
              "start_idx": 341,
              "end_idx": 345,
              "entity_en": "Fasting blood sugar"
            },
            {
              "entity_id": "T433",
              "entity": "尿白蛋白排泄率",
              "entity_type": "Test_items",
              "start_idx": 346,
              "end_idx": 353,
              "entity_en": "Urinary albumin excretion rate"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R234",
              "head_entity_id": "T415",
              "tail_entity_id": "T401"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R235",
              "head_entity_id": "T416",
              "tail_entity_id": "T402"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R236",
              "head_entity_id": "T417",
              "tail_entity_id": "T403"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R237",
              "head_entity_id": "T418",
              "tail_entity_id": "T404"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R238",
              "head_entity_id": "T421",
              "tail_entity_id": "T407"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R239",
              "head_entity_id": "T422",
              "tail_entity_id": "T408"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R240",
              "head_entity_id": "T423",
              "tail_entity_id": "T410"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R241",
              "head_entity_id": "T428",
              "tail_entity_id": "T410"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R242",
              "head_entity_id": "T424",
              "tail_entity_id": "T411"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R243",
              "head_entity_id": "T425",
              "tail_entity_id": "T412"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R244",
              "head_entity_id": "T432",
              "tail_entity_id": "T412"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R245",
              "head_entity_id": "T433",
              "tail_entity_id": "T412"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R246",
              "head_entity_id": "T429",
              "tail_entity_id": "T412"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R247",
              "head_entity_id": "T426",
              "tail_entity_id": "T413"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R248",
              "head_entity_id": "T431",
              "tail_entity_id": "T413"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R249",
              "head_entity_id": "T430",
              "tail_entity_id": "T413"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R250",
              "head_entity_id": "T427",
              "tail_entity_id": "T414"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R251",
              "head_entity_id": "T420",
              "tail_entity_id": "T419"
            }
          ],
          "sentence_en": "(1) Ginkgo biloba extract tablets (EGb761): The multiple components of this drug have a synergistic effect. It mainly improves blood rheology by reducing blood viscosity, thereby improving blood circulation; scavenges free radicals and inhibits lipid peroxidation of cell membranes; antagonizes platelet active factor (PAF), thereby inhibiting platelet aggregation; promotes synaptic remodeling and protects nerve cells. It is mainly used clinically for brain dysfunction caused by cerebral arteriosclerosis, diabetic retinopathy, and intermittent claudication caused by peripheral vascular disease. Brain and peripheral blood circulation disorders: including diabetic retinopathy and neurological disorders, age-related macular degeneration, intermittent claudication, etc. A study on residents in Taiwan showed that Ginkgo biloba extract tablets can effectively improve retinal capillary blood flow in patients with type 2 diabetic retinopathy, thereby alleviating diabetic retinopathy. Systematic evaluation results showed that the combination of Ginkgo biloba extract tablets with conventional treatment can further reduce fasting blood glucose and urinary albumin excretion rate in patients with diabetic nephropathy and improve blood rheology in patients. Domestic research shows that ginkgo leaf extract tablets combined with methylcobalamin for the treatment of diabetic peripheral neuropathy can significantly improve the clinical symptoms and nerve conduction velocity of patients with diabetic peripheral neuropathy, with an overall effective rate (significant and effective) of 88.9%."
        }
      ],
      "paragraph_en": "(1) Ginkgo biloba extract tablets (EGb761): The multiple components of this drug have a synergistic effect. It mainly improves blood rheology by reducing blood viscosity, thereby improving blood circulation; scavenges free radicals and inhibits lipid peroxidation of cell membranes; antagonizes platelet active factor (PAF), thereby inhibiting platelet aggregation; promotes synaptic remodeling and protects nerve cells. It is mainly used clinically for brain dysfunction caused by cerebral arteriosclerosis, diabetic retinopathy, and intermittent claudication caused by peripheral vascular disease. Brain and peripheral blood circulation disorders: including diabetic retinopathy and neurological disorders, age-related macular degeneration, intermittent claudication, etc. A study on residents in Taiwan showed that Ginkgo biloba extract tablets can effectively improve retinal capillary blood flow in patients with type 2 diabetic retinopathy, thereby alleviating diabetic retinopathy. Systematic evaluation results showed that the combination of Ginkgo biloba extract tablets with conventional treatment can further reduce fasting blood glucose and urinary albumin excretion rate in patients with diabetic nephropathy and improve blood rheology in patients. Domestic research shows that ginkgo leaf extract tablets combined with methylcobalamin for the treatment of diabetic peripheral neuropathy can significantly improve the clinical symptoms and nerve conduction velocity of patients with diabetic peripheral neuropathy, with an overall effective rate (significant and effective) of 88.9%."
    },
    {
      "paragraph_id": "36",
      "paragraph": "(2)复方丹参滴丸：由丹参、三七、冰片等药物组成，其中丹参的有效成分为水溶性丹参素，可提高机体抗凝和纤溶活性，抑制血小板聚集和释放前列环素类物质，抗凝血和抑制血栓形成；阻断羟自由基的产生，阻止脂质过氧化，是一种有效的氧自由基清除剂，临床上用于糖尿病肾病、视网病变和神经病变的治疗。一项纳入19个研究的荟萃分析结果显示，在常规治疗的基础上加用复方丹参滴丸，可显著减少24h尿蛋白总量，但是对血肌肝和血糖无影响。在中国疗非增殖性糖尿病视网膜病变患者中进行的一项随机对照研究，24周时眼底荧光血管造影及眼底检查结果均显示，高剂量和中剂量复方丹参滴丸组的有效的患者比例显著高于安慰剂组，且无临床不良事件发生。此外，复方丹参滴丸可以改善血瘀型糖尿病周围神经病变的血瘀症状，提高周围神经传导速度包括尺神经、腓总神经、腓肠神经和胫后神经的运动传导速度和感觉传导速度，有治疗和延缓其发展的作用。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(2)复方丹参滴丸：由丹参、三七、冰片等药物组成，其中丹参的有效成分为水溶性丹参素，可提高机体抗凝和纤溶活性，抑制血小板聚集和释放前列环素类物质，抗凝血和抑制血栓形成；阻断羟自由基的产生，阻止脂质过氧化，是一种有效的氧自由基清除剂，临床上用于糖尿病肾病、视网病变和神经病变的治疗。一项纳入19个研究的荟萃分析结果显示，在常规治疗的基础上加用复方丹参滴丸，可显著减少24h尿蛋白总量，但是对血肌肝和血糖无影响。在中国疗非增殖性糖尿病视网膜病变患者中进行的一项随机对照研究，24周时眼底荧光血管造影及眼底检查结果均显示，高剂量和中剂量复方丹参滴丸组的有效的患者比例显著高于安慰剂组，且无临床不良事件发生。此外，复方丹参滴丸可以改善血瘀型糖尿病周围神经病变的血瘀症状，提高周围神经传导速度包括尺神经、腓总神经、腓肠神经和胫后神经的运动传导速度和感觉传导速度，有治疗和延缓其发展的作用。",
          "start_idx": 0,
          "end_idx": 389,
          "entities": [
            {
              "entity_id": "T434",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 121,
              "end_idx": 126,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T435",
              "entity": "视网病变",
              "entity_type": "Disease",
              "start_idx": 127,
              "end_idx": 131,
              "entity_en": "Retinopathy"
            },
            {
              "entity_id": "T436",
              "entity": "神经病变",
              "entity_type": "Disease",
              "start_idx": 132,
              "end_idx": 136,
              "entity_en": "Neuropathy"
            },
            {
              "entity_id": "T437",
              "entity": "非增殖性糖尿病视网膜病变",
              "entity_type": "Disease",
              "start_idx": 208,
              "end_idx": 220,
              "entity_en": "Nonproliferative diabetic retinopathy"
            },
            {
              "entity_id": "T438",
              "entity": "血瘀型糖尿病周围神经病变",
              "entity_type": "Disease",
              "start_idx": 313,
              "end_idx": 325,
              "entity_en": "Blood Stasis Diabetic Peripheral Neuropathy"
            },
            {
              "entity_id": "T439",
              "entity": "复方丹参滴丸",
              "entity_type": "Drug",
              "start_idx": 3,
              "end_idx": 9,
              "entity_en": "Compound Danshen Dripping Pills"
            },
            {
              "entity_id": "T440",
              "entity": "复方丹参滴丸",
              "entity_type": "Drug",
              "start_idx": 170,
              "end_idx": 176,
              "entity_en": "Compound Danshen Dripping Pills"
            },
            {
              "entity_id": "T441",
              "entity": "24h尿蛋白总量",
              "entity_type": "Test_items",
              "start_idx": 182,
              "end_idx": 190,
              "entity_en": "Total 24-hour urine protein"
            },
            {
              "entity_id": "T442",
              "entity": "血肌肝",
              "entity_type": "Test_items",
              "start_idx": 194,
              "end_idx": 197,
              "entity_en": "Blood muscle liver"
            },
            {
              "entity_id": "T443",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 198,
              "end_idx": 200,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T444",
              "entity": "24周时眼底荧光血管造影",
              "entity_type": "Test",
              "start_idx": 235,
              "end_idx": 247,
              "entity_en": "Fundus fluorescein angiography at 24 weeks"
            },
            {
              "entity_id": "T445",
              "entity": "眼底检查",
              "entity_type": "Test",
              "start_idx": 248,
              "end_idx": 252,
              "entity_en": "Fundus examination"
            },
            {
              "entity_id": "T446",
              "entity": "血瘀",
              "entity_type": "Symptom",
              "start_idx": 326,
              "end_idx": 328,
              "entity_en": "Blood stasis"
            },
            {
              "entity_id": "T447",
              "entity": "复方丹参滴丸",
              "entity_type": "Drug",
              "start_idx": 265,
              "end_idx": 271,
              "entity_en": "Compound Danshen Dripping Pills"
            },
            {
              "entity_id": "T448",
              "entity": "复方丹参滴丸",
              "entity_type": "Drug",
              "start_idx": 303,
              "end_idx": 309,
              "entity_en": "Compound Danshen Dripping Pills"
            },
            {
              "entity_id": "T449",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 124,
              "end_idx": 125,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T450",
              "entity": "视网",
              "entity_type": "Anatomy",
              "start_idx": 127,
              "end_idx": 129,
              "entity_en": "Vision Network"
            },
            {
              "entity_id": "T451",
              "entity": "神经",
              "entity_type": "Anatomy",
              "start_idx": 132,
              "end_idx": 134,
              "entity_en": "nerve"
            },
            {
              "entity_id": "T452",
              "entity": "视网膜",
              "entity_type": "Anatomy",
              "start_idx": 215,
              "end_idx": 218,
              "entity_en": "Retina"
            },
            {
              "entity_id": "T453",
              "entity": "周围神经",
              "entity_type": "Anatomy",
              "start_idx": 319,
              "end_idx": 323,
              "entity_en": "Peripheral nerves"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R252",
              "head_entity_id": "T439",
              "tail_entity_id": "T434"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R253",
              "head_entity_id": "T449",
              "tail_entity_id": "T434"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R254",
              "head_entity_id": "T439",
              "tail_entity_id": "T435"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R255",
              "head_entity_id": "T450",
              "tail_entity_id": "T435"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R256",
              "head_entity_id": "T439",
              "tail_entity_id": "T436"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R257",
              "head_entity_id": "T451",
              "tail_entity_id": "T436"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R258",
              "head_entity_id": "T452",
              "tail_entity_id": "T437"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R259",
              "head_entity_id": "T444",
              "tail_entity_id": "T437"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R260",
              "head_entity_id": "T445",
              "tail_entity_id": "T437"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R261",
              "head_entity_id": "T448",
              "tail_entity_id": "T438"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R262",
              "head_entity_id": "T453",
              "tail_entity_id": "T438"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R263",
              "head_entity_id": "T446",
              "tail_entity_id": "T438"
            }
          ],
          "sentence_en": "(2) Compound Danshen Dropping Pills: It is composed of Danshen, Panax notoginseng, borneol and other drugs. The active ingredient of Danshen is water-soluble danshensu, which can improve the body's anticoagulant and fibrinolytic activity, inhibit platelet aggregation and release of prostacyclin-like substances, anticoagulate blood and inhibit thrombosis; block the production of hydroxyl free radicals and prevent lipid peroxidation. It is an effective oxygen free radical scavenger and is clinically used for the treatment of diabetic nephropathy, retinopathy and neuropathy. A meta-analysis of 19 studies showed that the addition of Compound Danshen Dropping Pills to conventional treatment can significantly reduce the total 24-hour urine protein, but has no effect on blood protein and blood sugar. A randomized controlled study conducted in Chinese patients with non-proliferative diabetic retinopathy showed that the results of fundus fluorescein angiography and fundus examination at 24 weeks showed that the effective proportion of patients in the high-dose and medium-dose Compound Danshen Dropping Pills groups was significantly higher than that in the placebo group, and no clinical adverse events occurred. In addition, Compound Danshen Drops can improve the blood stasis symptoms of blood stasis type diabetic peripheral neuropathy, increase the peripheral nerve conduction velocity including the motor conduction velocity and sensory conduction velocity of the ulnar nerve, common peroneal nerve, sural nerve and posterior tibial nerve, and have the effect of treating and delaying its development."
        }
      ],
      "paragraph_en": "(2) Compound Danshen Dropping Pills: It is composed of Danshen, Panax notoginseng, borneol and other drugs. The active ingredient of Danshen is water-soluble danshensu, which can improve the body's anticoagulant and fibrinolytic activity, inhibit platelet aggregation and release of prostacyclin-like substances, anticoagulate blood and inhibit thrombosis; block the production of hydroxyl free radicals and prevent lipid peroxidation. It is an effective oxygen free radical scavenger and is clinically used for the treatment of diabetic nephropathy, retinopathy and neuropathy. A meta-analysis of 19 studies showed that the addition of Compound Danshen Dropping Pills to conventional treatment can significantly reduce the total 24-hour urine protein, but has no effect on blood protein and blood sugar. A randomized controlled study conducted in Chinese patients with non-proliferative diabetic retinopathy showed that the results of fundus fluorescein angiography and fundus examination at 24 weeks showed that the effective proportion of patients in the high-dose and medium-dose Compound Danshen Dropping Pills groups was significantly higher than that in the placebo group, and no clinical adverse events occurred. In addition, Compound Danshen Drops can improve the blood stasis symptoms of blood stasis type diabetic peripheral neuropathy, increase the peripheral nerve conduction velocity including the motor conduction velocity and sensory conduction velocity of the ulnar nerve, common peroneal nerve, sural nerve and posterior tibial nerve, and have the effect of treating and delaying its development."
    },
    {
      "paragraph_id": "37",
      "paragraph": "其他中药提取物如血塞通注射液、丹红注射液和津力达颗粒等临床上也可用于治疗糖尿病微循环障碍疾病，但缺少长期大样本数据的支持。常用改善糖尿病微循环障碍药物的简要说明见表2和药品说明书。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "其他中药提取物如血塞通注射液、丹红注射液和津力达颗粒等临床上也可用于治疗糖尿病微循环障碍疾病，但缺少长期大样本数据的支持。常用改善糖尿病微循环障碍药物的简要说明见表2和药品说明书。",
          "start_idx": 0,
          "end_idx": 90,
          "entities": [
            {
              "entity_id": "T454",
              "entity": "血塞通注射液",
              "entity_type": "Drug",
              "start_idx": 8,
              "end_idx": 14,
              "entity_en": "Xuesetong Injection"
            },
            {
              "entity_id": "T455",
              "entity": "丹红注射液",
              "entity_type": "Drug",
              "start_idx": 15,
              "end_idx": 20,
              "entity_en": "Danhong injection"
            },
            {
              "entity_id": "T456",
              "entity": "津力达颗粒",
              "entity_type": "Drug",
              "start_idx": 21,
              "end_idx": 26,
              "entity_en": "Jinlida Granules"
            },
            {
              "entity_id": "T457",
              "entity": "糖尿病微循环障碍疾病",
              "entity_type": "Disease",
              "start_idx": 36,
              "end_idx": 46,
              "entity_en": "Diabetes microcirculatory disorders"
            },
            {
              "entity_id": "T458",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 65,
              "end_idx": 68,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T459",
              "entity": "微循环障碍",
              "entity_type": "Symptom",
              "start_idx": 68,
              "end_idx": 73,
              "entity_en": "Microcirculatory disorders"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R264",
              "head_entity_id": "T454",
              "tail_entity_id": "T457"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R265",
              "head_entity_id": "T455",
              "tail_entity_id": "T457"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R266",
              "head_entity_id": "T456",
              "tail_entity_id": "T457"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R267",
              "head_entity_id": "T459",
              "tail_entity_id": "T458"
            }
          ],
          "sentence_en": "Other Chinese herbal extracts such as Xuesetong injection, Danhong injection and Jinlida granules can also be used clinically to treat diabetic microcirculatory disorders, but there is a lack of long-term large sample data to support this. A brief description of commonly used drugs for improving diabetic microcirculatory disorders is shown in Table 2 and the drug instructions."
        }
      ],
      "paragraph_en": "Other Chinese herbal extracts such as Xuesetong injection, Danhong injection and Jinlida granules can also be used clinically to treat diabetic microcirculatory disorders, but there is a lack of long-term large sample data to support this. A brief description of commonly used drugs for improving diabetic microcirculatory disorders is shown in Table 2 and the drug instructions."
    },
    {
      "paragraph_id": "38",
      "paragraph": "5 总结与展望",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "5 总结与展望",
          "start_idx": 0,
          "end_idx": 7,
          "entities": [],
          "relations": [],
          "sentence_en": "5. Summary and Outlook"
        }
      ],
      "paragraph_en": "5. Summary and Outlook"
    },
    {
      "paragraph_id": "39",
      "paragraph": "本共识从微循环障碍在糖尿病慢性并发症发生中的机制入手，分析其临床表现及药物治疗原则，以期帮助临床医生提高对糖尿病患者微循环障碍的重视程度，在临床实践中实现早期识别、早期诊断、早期预防和治疗，改善糖尿病患者的预后。在我国，许多改善微循环障碍的药物仍缺乏足够的循证医学证据，今后仍需开展相关大型前瞻性临床研究，为糖尿病患者微循环障碍治疗的安全性、个体化用药提供更多的临床循证依据。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "本共识从微循环障碍在糖尿病慢性并发症发生中的机制入手，分析其临床表现及药物治疗原则，以期帮助临床医生提高对糖尿病患者微循环障碍的重视程度，在临床实践中实现早期识别、早期诊断、早期预防和治疗，改善糖尿病患者的预后。",
          "start_idx": 0,
          "end_idx": 106,
          "entities": [
            {
              "entity_id": "T460",
              "entity": "微循环障碍",
              "entity_type": "Symptom",
              "start_idx": 4,
              "end_idx": 9,
              "entity_en": "Microcirculatory disorders"
            },
            {
              "entity_id": "T461",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 10,
              "end_idx": 13,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T462",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 53,
              "end_idx": 56,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T463",
              "entity": "微循环障碍",
              "entity_type": "Symptom",
              "start_idx": 58,
              "end_idx": 63,
              "entity_en": "Microcirculatory disorders"
            },
            {
              "entity_id": "T464",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 97,
              "end_idx": 100,
              "entity_en": "diabetes"
            }
          ],
          "relations": [
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R268",
              "head_entity_id": "T460",
              "tail_entity_id": "T461"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R269",
              "head_entity_id": "T463",
              "tail_entity_id": "T462"
            }
          ],
          "sentence_en": "This consensus starts with the mechanism of microcirculatory disorders in the occurrence of chronic complications of diabetes, analyzes its clinical manifestations and drug treatment principles, in order to help clinicians increase their attention to microcirculatory disorders in diabetic patients, achieve early identification, early diagnosis, early prevention and treatment in clinical practice, and improve the prognosis of diabetic patients."
        },
        {
          "sentence_id": "1",
          "sentence": "在我国，许多改善微循环障碍的药物仍缺乏足够的循证医学证据，今后仍需开展相关大型前瞻性临床研究，为糖尿病患者微循环障碍治疗的安全性、个体化用药提供更多的临床循证依据。",
          "start_idx": 106,
          "end_idx": 188,
          "entities": [
            {
              "entity_id": "T465",
              "entity": "微循环障碍",
              "entity_type": "Symptom",
              "start_idx": 8,
              "end_idx": 13,
              "entity_en": "Microcirculatory disorders"
            },
            {
              "entity_id": "T466",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 48,
              "end_idx": 51,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T467",
              "entity": "微循环障碍",
              "entity_type": "Symptom",
              "start_idx": 53,
              "end_idx": 58,
              "entity_en": "Microcirculatory disorders"
            }
          ],
          "relations": [
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R270",
              "head_entity_id": "T467",
              "tail_entity_id": "T466"
            }
          ],
          "sentence_en": "In my country, many drugs that improve microcirculation disorders still lack sufficient evidence-based medicine. In the future, relevant large-scale prospective clinical studies are still needed to provide more clinical evidence-based basis for the safety and individualized medication of microcirculation disorders in diabetic patients."
        }
      ],
      "paragraph_en": "This consensus starts with the mechanism of microcirculatory disorders in the occurrence of chronic complications of diabetes, analyzes its clinical manifestations and drug treatment principles, in order to help clinicians increase their attention to microcirculatory disorders in diabetic patients, achieve early identification, early diagnosis, early prevention and treatment in clinical practice, and improve the prognosis of diabetic patients. In my country, many drugs that improve microcirculatory disorders still lack sufficient evidence-based medicine. In the future, relevant large-scale prospective clinical studies are still needed to provide more clinical evidence for the safety and individualized use of drugs in the treatment of microcirculatory disorders in diabetic patients."
    }
  ]
}